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CHAPTER 1
REVERSE PHASE CHROMATOGRAPHIC THEORY AND PRACTICE
I. INTRODUCTION
Over the past five years, our laboratory has been particularly 
interested in the chromatographic separation and subsequent quantita­
tion of catecholamine and indoleamine related compounds in biological 
fluids and tissues. A large variety of such procedures currently exist 
for the determination of these compounds.However, most of these pro­
cedures can only be used to quantitate one to four of these many different 
c o m p o u n d s t h i s  can lead to an incomplete picture concerning the 
physiological profile of the associated tyrosine and tryptophan path­
ways. Also, these procedures require a considerably diverse array of 
mobile phases, a variety of chromatographic columns, and rather extensive 
sample manipulations prior to quantitation. In short, each of these 
assays requires a unique chromatographic system dedicated to that par­
ticular analysis. We have also recently developed a substantial number 
of different enzymatic assays in our laboratory by focusing on the 
chromatographic determination of products. Again, each of these pro­
cedures requires a distinct chromatographic system. In order to 
minimize the total number of chromatographs required, we decided to 
develop appropriate conditions to permit the simultaneous determination
1
of as many catecholamine and indoleamine metabolites as possible. The 
compounds of interest are summarized in Table 1-1.
II. REVERSE PHASE LIQUID CHROMATOGRAPHIC THEORY
A. Fundamental Definitions
Modern partition chromatography began in the early 1940's.
At that time, liquid chromatographic columns were prepared by lightly 
coating silica beads with thin films of water or other polar com­
pounds. This material was packed into a tube, and a nonpolar liquid 
was allowed to flow through the packed column. The silica beads were 
referred to as the stationary support, the polar coating was called 
the stationary phase, and the nonpolar liquid was known as the mobile 
phase. This general type of liquid chromatography was later labeled
normal phase chromatography, NPC, and is schematically shown in Fig. 1-lA.
In contrast to NPC, the more commonly employed reverse phase 
chromatography (RPC) incorporates a nonpolar coating (see Fig. 1-lB).
The stationary phase for modern reverse phase systems is typically 
prepared by reacting the exposed silicic acid groups on silica beads 
with alkyl chlorosilanes to produce a chemically bonded and uniformly 
distributed organic film over the surface of the particles
^  -Sl-O-SÏCCHp^CHj-S,i-OH + Cl-Si(CH2)^^yCH^ --------- >1
An entirely aqueous solution may be used as the mobile phase. However, 
an organic diluent is frequently added to the mobile phase to modify 
the chromatographic parameters.
The resulting chromatographic separation arises from differences
Table 1-1. Structures and Abbreviations of Some Catecholamines, Indoleamines and Related Metabolites
Compound structure Abbrevia­
tion ^ 1 * 2 ^3 ^5
Catecholamines and Related Metabolites
Epinephrine EPI OH OH OH H H CH
3-Methoxytyramine
n ?3 fe
3-MT OH OCHg H H H H
Dopamine DA OH OH H H H H
3,4-Dihydroxyphenylalanine ( DOPA OH OH H H COOH H
Norepinephrine R
^  H 0
NE OH OH OH H H H
Normetanephrine NORMET OH OCH3 OH H H H
Tyrosine TYR OH H H H COOH H
Homovanillic acid
3.4-Dihydroxyphenylacetic acid 
3 ,4-Dihydroxybenzylamine
3.4-Dihydroxymandelic ac id 
Vanil1 ylmandelic acid
3.4-Dihydroxyphenylglycol
3-Methoxy-4-hydroxyphenethylglycol
?3
CH-R4 -R5
HVA OH OCH3 H COOH - -
DOPAC OH OH H COOH - -
DHBA OH OH H NHg - -
DOMA OH OH OH COOH - -
VMA OH OCH3 OH COOH - -
DOPEG OH OH OH CHg OH -
MOPEG OH OCHg OH CHg OH -
Table 1-1 (continued)
Compound Structure Abbrevia­
tion
R 2 ^5 ^ 6
5-HTOL CHg CH OH
5-HTP CHg CH NH^ COOH - -
5-HIAA CH^ COOH - - - -
5-HT CHg CH^ NH^ - - -
nMET CH^ CHg - NH - CHg
5-HICA COOH - - - - -
N-Ac-5-HT CHg CHg - NH - COCHg
Indoleamines and Related Metabolites
5-Hydroxytryptophol
5-Hydroxytryptophan
5-Hydroxyindole-3-acetic acid
5-Hydroxytryptamine
5-Hydroxy-Nw-methyltryptamine
5-Hydroxyindole-3-carboxylic acid 
N-acety1-5-hydroxytryptamine
COOH
Tryptophan
Melatonin
H
TP
3 MEL
opolar stationary phase
immiscible nonpolar 
mobile phase
NORMAL PHASE
A
o °  o  ^
REVER
B
nonpolar 
- A  phase
SE PHASE
Figure 1-1. Illustration Comparing Normal Phase with Reverse Phase 
Chromatography. Normal phase (Figure A) consists of a polar 
stationary phase adsorbed onto a silica support. This is in con­
trast to reverse phase chromatography (Figure B) which consists 
of a nonpolar stationary phase chemically bonded onto a silicia 
support.
6in the equilibrium distribution of the solutes, or sample components, 
between the mobile and stationary phases. The greater the difference in 
solubility for two solutes in the stationary phase, the greater 
the degree of separation. Consider, for example, the distribution 
of solute i between two immiscible phases, o and a, at constant tempera­
ture and pressure:
io Cl-1)
where o represents a nonpolar, organic stationary phase and a represents 
an aqueous mobile phase. The ratio of solute concentrations in the two 
phases is given by the equilibrium distribution constant, K:
K = ^  (1-2)
where [i]^ and [i]^ are the molar concentrations of solute i in the organic
and aqueous phases, respectively. Simply put, the larger the value of K, 
the greater the fraction of solute i in the stationary phase at any 
given instant and the longer the time i will spend in the chromatographic 
column. Equation 1-2 can also be expressed as:
K - (1-3)
"  "  V o
where n and n are the number of millimoles of the solute in the 
o a
organic and aqueous phases, respectively. is the total volume of 
the mobile phase within the column at any given time (ml) and is 
commonly called the dead volume or void volume. is the volume 
occupied by the coating on the stationary phase.
Rearranging eq. 1-3 yields 
V n
k '  =  ^  C l - 4 )
a a
where k' is an important parameter termed the capacity factor. For a
given column, V and V are constant, or 
o a
k'aK (1-5)
Thus, measurements of capacity factors for various solutes under fixed 
chromatographic conditions provide direct evaluations of the dis­
tribution coefficients for these solutes.
Experimentally the determination of the column void 
volume, V^, is obtained from
V = (F) (,t ) Cl-6 )
a o
where F is the average flow velocity in ml/min and t^ is the retention 
time of a non-retained component, i.e., a solute which experiences no 
interaction with the stationary phase. V^, the volume of the coating 
on the stationary phase, can also be written as:
(F)(t -t )
Vo = —
where t is the retention time for a retained solute, 
r
Combining eqs. 1-4, 1-6, and 1-7, we obtain 
t -t
k' = ( - ^ )  (1 -8 )
t
o
Therefore, k' for any solute can be conveniently determined by simply 
measuring the retention time of the solute and that of a nonretained 
component. These measurements are illustrated in Fig. 1-2. Because
1 0 -2
inject
mm
Figure 1-2. Calculation of the Capacity Factor, k', from a 
Chromatogram, and to can be measured in units of time or 
distance.
9k' is directly related to K, it is independent of the column length and 
flow rate to a first approximation. This makes k' a far more useful 
parameter than the retention time for chromatographic investigations.
Another useful parameter which allows the chromatographer to 
quantitatively evaluate a separation between two solutes is the 
separation factor, a:
a = ^  (1-9)
‘^ 1
where k^ and k^ refer to the capacity factors for solutes 1  and 2  
respectively. By convention, k^ is always greater than kj^ . The 
separation factor is an indirect measure of the distance between band 
centers for two neighboring peaks; the larger the value for a, the 
better the separation. The essential parameters and the associated 
calculation of the separation factor for two well-separated solutes 
is exhibited in Fig. 1-3.
A third experimental parameter that is important in evaluating 
the performance of a chromatographic system is the number of theoretical 
plates, N. It is defined as:^^’^^
t y
N = Cl-10)
where t is the retention time for the solute and o is the band variance 
r
in units of time. N is, thus, a dimensionless quantity which is 
empirical in nature and provides some measure of band spreading, The 
extensive and exclusive use of N to completely characterize band 
broadening and efficiency of a chromatographic system has been seriously 
questioned due to its dependence on a particular solute. However, as 
a general rule, the larger the reported value for N, the greater the
10
(X =
( S )
( ^ )
1 4 .2 -2 .0
2.0
=  1 .7
9 .4 -2 .0
2.0
inject
20 min
Figure 1-3. Calculation of the Separation Factor, o< , from a 
Chromatogram. t2 , t-j,and to can be measured either as units of 
time or distance. The chromatogram illustrates the separation 
of two well-resolved peaks.
11
overall column efficiency. To derive N from an actual chromatogram, 
eq. 1-10 will have to be altered. Assuming Gaussian-shaped peaks, the 
width measured at the point where the peak is one-half of its maximum 
value, can be shown to be:^^
W^y2  = 2 o/2 1 n 2  (1 - 1 1 )
Solving for o and substituting into equation 1-10 we arrive at;
^r 2
N = 5.54 (t^ )  (1-12)
"b/ 2
This equation is preferred since the resulting value of N is not signifi­
cantly affected by the tailing observed for some peaks (see, e.g.. Fig. 1-5A) 
Thus, equation 1-12 provides more uniformity in comparing the efficiencies 
of different columns. A calculation of N is illustrated in Fig. 1-4.
B. The Nature of Band Broadening.
Band broadening is the phenomenum which results from an increase 
in the width of a solute band as it migrates down the column. Excessive 
band broadening represents a degradation of the narrow zone of solute 
molecules initially introduced in the injection. This degradation is 
a major contributor to overlapping peaks and poor separations.
There are many characteristics which contribute to band broadening
in liquid chromatography, although only two are of primary importance:
mass transfer and mobile phase effects.
Mass transfer contributions to band broadening are determined 
by two fundamental factors, the rate of diffusion of the solute within 
the stationary phase and the rates of absorption into and desorption 
out of the stationary phase. The mechanism of mass transfer can be
12
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Figure 1-4. Calculation of the Number of Theoretical Plates, N, 
for a Chromatographic Column. W | ) / 2 the width of the peak at 
one half the peak height. W b / 2  and tf can be measured in units 
of time or distance.
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described as follows. When a solute molecule is absorbed into the sta­
tionary phase, it immediately begins to fall behind the other solute mole­
cules as they proceed with the mobile phase down the column. Diffusion 
within the stationary phase may enhance or detract from this falling behind 
as the solute randomly migrates in the chemically bonded coating. After 
some time, the molecule is desorbed back into the solvent stream. It 
resumes its journey down the column until it reabsorbs into another 
stationary particle. This percolating effect results in some molecules 
lagging behind, while others migrate ahead of, the central portion 
of the solute zone. Narrow solute zones are preserved by very small 
solute diffusivities within the stationary phase along with rapid 
absorption and desorption.
72Using a random walk model, Giddings calculated the contri­
bution of mass transfer to column efficiency as
LD d+k')^
N  §-=----- (1-13)
 ^ qk’d V
where L is the column length (cm), D^ is the solute diffusivity in the
2
stationary phase (cm /sec), q is a particle shape factor (typically 2/3 
for a uniform liquid film), v is the flow velocity (cm/sec) and d is the 
particle diameter of the packing material (cm).
Mobile phase contributions to band broadening are partly deter­
mined by flow phenomena which result from the tortuous paths the 
solution must follow before emerging from the column. As the solution 
is forced through the column, its velocity at different points in the 
column varies. Consequently, molecules being carried in such a stream 
will have their individual velocities altered as they pass from one
14
interstitial space to another. Some molecules, by following relatively
open passageways, will have a somewhat faster overall velocity.
Others will become entangled in restricted zones and fall behind,
72
Giddings has also estimated the contribution of flow-profile effects 
to column efficiency:
Nj. = L/Ad (1-14)
where A is a function of the packing structure. As in the stationary
phase, diffusion can also occur within the mobile phase. Its contri-
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bution is expressed as:
LD
N „  ^  Cl-15)
Ovd^
where is the diffusivity of the solute in the mobile phase and 0  is
a function of the packing structure.
The combined expression for the total number of theoretical
plates is then the sum of eqs. 1-13, 1-14, and 1-15,
LD LD d+k')^
N = N + N + N = (— ^ ----). (1-16)
^ ® nd V Ad qk'd V
Thus, to increase the total number of theoretical plates and, thereby,
the efficiency of the column, one can increase the column length, (L),
decrease the particle size of the packing material (d), or decrease the
flow velocity (v) of the chromatographic system.
C. Resolution.
The previous discussion describes the factors which create
band spreading of the injected solute molecules. As mentioned earlier,
this, phenomenon is of concern because it may lead to serious over-
15
lapping of chromatographic peaks. Fig. 1-5 very clearly illustrates 
the importance of minimizing this problem. Fig. 1-5A was obtained 
from component mixture using a highly inefficient column (N=600), 
whereas Fig. 1-5B is a chromatogram of the same mixture run on a high 
efficiency column (N=3000). Results such as those seen in Fig. 1-5A 
are undesirable for three primary reasons. First, the total number 
of individual compounds that can be determined in a single chromato­
graphic run is considerably decreased. Secondly, the elution of other, 
unsuspected solutes may be obscured under the observed peaks. Finally, 
overlapping peaks are extremely difficult to quantitate. Quantitative 
measurements are frequently obtained by measuring the area underneath 
each peak, and it is extremely difficult to assign an appropriate 
fraction of the total area to a specific solute. Thus, measurements 
of low resolution peaks may require the use of complex, computer-aided 
deconvolution techniques'^to obtain an acceptable level of precision.
The degree to which two adjacent bands are separated is termed 
resolution and is defined as the distance between band centers divided 
by the average band width:
Since the values of W for closely adjacent bands are approximately 
equal, and assuming the peaks are Gaussian, it can be shown that
Substituting into eqn. 1-17, we arrive at
©inject
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Figure 1-5. The Effect of Band Broadening on the Separation of a Three Component Mixture. Chromato­
gram A (left) was obtained from a low efficiency column where extensive band spreading occurred. 
Chromatogram B (right) was obtained from a high efficiency column employed to minimize band broadening. 
Peaks: DOPAC (1), 5-HIAA (2), and 5-HICA (3).
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R . - 5 ^  (1-18)
An example illustrating how R is obtained is presented in Fig. 1-6.
For optimal analytical purposes, very little overlapping should occur. 
This corresponds to a minimum resolution of 1.5, for which the purity 
of neighboring peaks exceeds 99%.^^
The primary goal of any chromatographic procedure is to 
adequately separate and resolve the individual compounds of interest 
in a complex mixture. The primary task of the chromatographer is to 
establish the chromatographic parameters necessary to provide this 
resolution. A modified form of equation 1-18 more conveniently 
exhibits the experimental parameters involved. This can be derived 
from the equations already discussed. Assuming that the efficiencies 
are approximately equal for two adjacent peaks, eqs. 1 - 1 0  and 1-18 are 
combined to yield
R  =  Æ  C l -  %  C l - 1 9 )
t2
The ratio of retention times, t^ytg, for two different solutes can be
obtained from eq. 1 -8 :
t. (k'+ll
=  TkJ+iJ (1-20)
Substituting this into equation 1-19 we obtain
Finally, using equation 1-9, we arrive at the following important 
relationship :
18
R =
1 1 .5 -9 .5
z  1.33
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Figure 1-6. Calculation of the Resolution, R, of Two Neighboring 
Chromatographic Peaks. The width of the peak, Wy ^ was obtained by 
drawing tangential lines down each side of a peak until they intersect 
the baseline. Wj, is the distance between these two lines measured 
at the baseline.
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From eq. 1-22, we see that the resolution is a rather direct 
function of three experimental parameters: N, k' and a. An increase
in any one of these parameters should, therefore, increase the resolution 
between adjacent chromatographic peaks. It follows that lengthening 
the column, reducing the particle size, or decreasing the flow rate 
should cause an improvement in R. Capacity factors and separation 
factors can be altered by changes in the nature of either the stationary 
phase or the mobile phase. In the following pages, we report adjustments 
of these two items which were undertaken in an attempt to separate 
and resolve ten biologically important catecholamine and indoleamine 
related compounds.
III. MATERIALS AND METHODS
A. Liquid Chromatographic System.
Pump. A Waters (Milford, MA.) Model 6000 double reciprocating 
pump was used for solvent delivery.
Injector. A Waters Model U 6 K was fitted with a 20 microliter 
fixed volume loop.
Column. This was a 150x4.6 mm reverse phase Ultrasphere column 
packed with 5 micron, octadecyl-coated spherical particles.
It was purchased from Beckman (Irvine, CA) as part no. 235330.
Detector. The detector was homemade by our local machine shop 
from one-half inch thick plexiglass sheets (Fig. 1-7). A 5 mil teflon 
spacer was placed between the two machined plastic blocks. A notch cut 
in the spacer served as solvent path. This unit was obtained from
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Figure 1-7. Diagram for the Construction of an Electrochemical Detector.
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BioAnalytical Systems (W. Lafayette, IN) as part no. TG-SM.. The 
electrochemical detector was packed with carbon paste and operated 
at a potential of +0.80 volts vs. SCE.
Carbon Paste. 3 grams of carbon, obtained from Ultra Carbon 
(Bay City, MI) as part no. UCP-l-M, and 2 ml of mineral oil were 
placed into a 100 ml 24/40 ground glass round bottom flask. 50 ml of 
benzene were added and the solution was mixed well for ca. 1 0  min.
The flask was placed on a rotary evaporator and the benzene removed.
The last traces of solvent were removed by placing the flask containing
the carbon paste on a high vacuum line for 1  hour.
Electronics. The potential controller and current monitoring
4
unit was identical to that previously described.
Reference electrode. A saturated calomel electrode (SCE) was
prepared in a similar fashion to that described in reference 5. The
SCE was separated from the chromatographic stream by a piece of 3 mm 
Vycor rod held onto the tip of the electrode with a piece of teflon 
tubing. The holder for the SCE was obtained from BioAnalytical Systems 
(W. Lafayette, IN) as part no. RC-1.
Syringe. A 50 pi P/S Pressure-Lok syringe, series B-IQO, 
with a 0.020 inch o.d. needle was obtained from Supelco (Beliefonte, PA).
Strip Chart Recorder. An Omniscribe dual pen recorder was 
obtained from Houston Instruments (Austin, TX).
Filtration Device. A Millipore 47 mm filtering apparatus 
fitted with a stainless steel screen was obtained from Millipore 
(Bedford, MA) as part no. XXIO 047 30. The filters used for purifying 
the chromatographic solvent were also obtained from Millipore as part
22
no. HAWP 047 00.
B. Reagents.
All reagents were purchased at the highest available purity 
and used without subsequent purification. The individual compounds 
were obtained from the following sources:
From Aldrich Chemical Co. (Milwaukee, WI):
3.4-dihydroxyphenylacetic acid (POPAC)
3-hydroxytyramine hydrochloride (DA)
3-(3,4-dihydroxyphenyl)-DL-alanine (DOPA)
3-methoxy-4-hydroxyphenylacetic acid (homovanillic acid) (HVA)
serotonin(5-hydroxytryptamine)creatinine sulfate monohydrate 
(5-HT)
5-hydroxyindole-3-acetic acid (5-HIAA)
DL-5-hydroxytryptophan (5-HTP) 
norepinephrine hydrochloride (HE) 
epinephrine (EPI)
3-0-methyltyramine hydrochloride (3-MT)
3.4-dihydroxybenzylamine hydrobromide (DHBA) 
5-hydroxy-N^-methyltryptamine oxalate (nMET)
3.4-dihydroxyphenylglycol (DOPEG)
From Sigma Chemical Co. (St. Louis, MO):
normetanephrine hydrochloride (NORMET)
5-hydroxytryptophol (5-HTOL)
From Pfaltz and Bauer (Flushing, NY):
3-methoxy-4-hydroxymandelic acid (VMA)
3.4-dihydroxymandelic acid (DOMA)
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From Eastman Kodak (Rochester, NY):
Sodium octyl sulfate (SOS)
Structures for all the above compounds except SOS can be found in 
Table 1-1 (vide supra). All other reagents were purchased at the 
highest available purity from commercially available sources. The water 
used was double distilled from an all glass apparatus.
C. Solutions.
Mobile Phase. The chromatographic buffer was prepared by 
dissolving 117.64 g of trisodium citrate dihydrate (0.050 M) and 
84.04 grams of citric acid monohydrate (0.050 M) into 8.0 liters of 
distilled water. Portions of this bulk solution were used to prepare 
the various mobile phases that were tested. The pH was adjusted by 
the dropwise addition of 1 M NaOH or 2 M HCl while monitoring with a 
pH meter. Methanol was added, as appropriate, for various test solu­
tions. Prior to use, the solution was passed through a 0.45 
micron Millipore filter.
Stock solutions. Solutions of the catecholamine- and indole-
amine-related compounds were individually prepared by dissolving ca.
78
2 mg of each compound into 100 ml of deoxygenated water. Portions 
of these solutions were stored in small vials at -4®C for future 
use.
IV. RESULTS
A. Optimization of N.
Our initial work with the various metabolites of catecholamines 
and indoleamines began in 1978 with an attempt to quantitate DOPAC 
and 5-HIAA in brain tissue. A 27-35 ym anion exchange packing material
24
called Zipax SAX (DuPont, Wilmington, DE) was selected for this work.
The resin was hand-packed into glass columns according to the method 
81
of Kirkland. A typical chromatogram resulting from an ethyl acetate 
extract of brain tissue is shown in Fig. 1-8A. Note the extremely 
broad and overlapping peaks. Also note that the peak for DOPAC is 
only barely discernible as a shoulder on the peak for the internal 
standard, 5-HICA. The value for 5-HIAA in whole mouse brain determined 
using these conditions was 435±111 ng/gram wet weight (n=ll). Although 
this value was in fairly close agreement with those reported by others 
using alternative procedures ^ it was felt that an improvement
could certainly be made to increase the amount of available data from 
the chromatogram. As luck would have it, a somewhat used reverse phase 
column was found and inserted into our chromatographic system. The 
reasons for considering reverse phase chromatography were: 1 ) the
rapidly expanding availability of microparticulate (5-10 pm particle 
diameter, reverse phase) columns, 2 ) the excellent stability of the 
columns toward organic-aqueous solvents, 3) the capability of reverse 
phase columns to operate as either cation or anion exchange columns 
through the addition of ion-pairing reagents, and 4) the capability 
of these columns to withstand a pH range of 1 to 7.
1. Effect of Particle Size on N.
Our first reverse phase column was a 300 x 4.6 mm stainless 
steel unit packed with octadecyl-coated, 10 pm silica particles. A 
typical chromatogram obtained from an ethyl acetate extract of 
whole mouse brain tissue is shown in Fig. 1-8B. Note the considerable 
improvement in peak capacity for the 1 0  pm reverse phase column as
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Figure 1-8. The Effect of Particle Size on Chromatographic Resolution. The figure illustrates 
chromatograms obtained from two columns packed with stationary supports of different sizes. Fig. 
A is from a hand packed 30-40 micron bed. Fig. B is from a commercially prepared reverse phase 
column containing 10 micron particles. N, as calculated from peak four, is 450 and 900 for Fig. 
A and B, respectively. Peaks: HVA (1), DOPAC (2), 5-HICA (3), and 5-HIAA (4).
26
compared to the previously employed Zipax resin of Fig. 1-8A. Four 
compounds are now easily resolved. Although this separation was ob­
viously encouraging, we still had some reservations about using these 
columns. The disadvantages of such reverse phase columns are: 1)
higher operating pressures require the use of all-metal fittings and 
tubings, 2 ) the cost of a typical reverse phase column is considerably 
higher than the hand-packed glass columns, and 3) microparticulate 
columns are much more easily clogged by particulate matter. However, 
after careful consideration, we felt that the potential increase in 
data obtained per sample clearly outweighed these relatively minor 
problems.
2. Limitations of Flow Rate and Column Length.
Both N and R, as seen in equations 1-16 and 1-22, increase 
with increased column length. But, extensive increases in L eventually 
lead to unacceptably large back pressures. Increasing the flow rate, 
as seen in Fig. 1-9, similarly leads to excessive operating pressures. 
Thus, increases in either length or flow rate rapidly reach the 
pressure limitations of the equipment. In particular, the noise 
dampening component of the system is rated at a maximum pressure 
of only 3000 p.s.i.
It should also be noted that there exists an optimal flow 
velocity, at which the system exhibits the maximum number
of theoretical plates for the components of interest. However, it 
is usually found that the retention times for the most strongly re­
tained components are excessively large at v . The increased time
opt
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Figure 1-9. The Effect of Flow Rate on Chromatographic Operating Pressures. 
The data was obtained from a 30 cm jiBondapak CDS column packed with lOji 
particles.
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required for each injection drastically restricts the number of samples 
which can be conveniently run in a single day. Thus^ optimal re­
solution must be partially sacrificed for greater separation speed by 
using higher flow rates. The compromise for these conflicting needs 
was a 150 x 4.6 mm column with 5 pm particles operated at greater flow 
rates than the 300 x 4.6 mm column with 10 p particles. This 
unit contained enough plates to adequately separate the components 
of interest, and, by increasing the flow from 1.1 to 1.5 ml/min, a 
considerable savings in total analysis time was achieved.
B. Optimization of Separation by Changes in the Mobile Phase.
Three mobile phase parameters were extensively investigated 
to find the optimal k ’ values for the individual components of 
interest. These were the solvent strength, the pH and ion-pairing 
agents. After adjustment of the tested parameter, the system was 
allowed time to reestablish equilibrium. This required one hour for 
changes in solvent strength and pH and six hours for adjust­
ments in the ion-pairing agent. Subsequent assessment of retention 
time, t^, and half-peak width, values were employed in equations
1-8, 1-9, 1-12, and 1-22 to determine k', a, N, and R. The following 
discussion focuses on k' since this is the fundamental value which 
causes alterations in a, N, and R.
1. Solvent Strength.
Changes in k' can be readily produced by the addition of 
miscible organic solvents to aqueous buffers used as the mobile phase. 
Adding organic solvents generally leads to a decrease in k' with 
reverse phase systems. This is primarily due to an increase in
29
solubility of the partially hydrophobic solute molecules in the 
mobile phase. Using methanol as the mobile phase organic modifier, 
we obtained the results shown in Figs. 1-10 and 1-11, For all the 
compounds examined, the k' values asymptotically approached zero with 
increasing concentrations of MeOH. It is important to note that the 
observed elution order was independent of the alcohol concentration.
An increase in methanol only served, to simultaneously decrease the 
retention times for all the components. The maximum limit for MeOH 
when using a carbon paste electrode was judged to be 1 0 % on a volume/ 
volume basis. Higher concentrations destroy the electrode by dissolving the 
Nujol used as a binder.
2. pH Adjustments and Ion Suppression.
Hydrogen bonding between the aqueous mobile phase and a charged
solute results in a greater solubility of the solute in the mobile
phase. The degree of hydrogen bonding can be very precisely adjusted
by using buffered solvents having a pH within ±0.5 units of the pK^
of the solute. The effect of the mobile phase pH on k' values is
illustrated for a number of relevant compounds in Fig. 1-12. The pH
range of 3.5 to 5.5 produces dramatic changes in k' for the acid
metabolites, while leaving the amine, neutral, and zwitterionic
metabolites virtually unaffected. These results can be explained
with the aid of Fig. 1-13. The pK^ values for carboxylic acids
like the investigated metabolites are approximately 
824.5. As the pH is lowered, these compounds become protonated and, 
consequently, lose their negative charge. This causes a decrease 
in hydrogen bonding between the solute and the mobile phase.
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Figure 1-lOA. The Effect of Methanol on k' for Various Acids 
and Alcohols. Chromatographic conditions: flow rate = 1.3 ml/min, 
citrate buffer (0.050 K, pH=5.0).
31
8.
7.
6.
5.
4.
.3-MT
3.
5-K jiMET
2.
i-HTP
0.0L-
0.0 8. 10.2 4 6
% METHANOL
Figure 1-lOB. The Effect of Methanol on k' for Various Amines
and Amino Acids. Chromatographic conditions: flow rate = 1.3 ml/min,
citrate buffer (0.050 M, pH=5.0).
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Figure 1-lOC. The Effect of Methanol on k' for Various Amines
and Amino acids. Chromatographic conditions: flow rate = 1 . 3  ml/min,
citrate buffer (0.050 M, pH=5.0).
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Figure 1-11. Typical Chromatograms Illustrating the Effect of Increasing the Strength of 
the Mobile Phase by the Addition of Methanol. Chromatographic conditions: 150 x 4.6mm Ultra­
sphere CDS column, flow rate = 1.3 mls/min, 0.10 M citrate buffer. Figure A - no methanol. 
Figure B - 10% methanol. Peaks: DA (1), 5-HTP (2), DOPAC (3), 5-HT (4), nMET (5), S-HIAA (6 ),
5-HICA (7), and HVA (8 ).
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Figure 1-12. The Effect of pH on the k' of Selected Acids, 
Alcohol, Amines and Amino Acids. Chromatographic conditions: 
10% methanol, flow rate = 1.3 ml/min, citrate buffer (0.10 M), 
pH = 4.6.
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Figure 1-13. An Illustration Describing the Retention Mechanism of 
Ion Suppression for Weak Acids. At low mobile phase pH's(left), the 
acids are predominately protonated, creating an increase in their 
adsorption into the stationary phase. Removal of the acidic hydrogen 
by increasing the mobile phase pH, decreases the retention of the 
acid, primarily through an increase in hydrogen bonding of the solute 
with the mobile phase.
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The resultant increase in hydrophobicity of the solute also leads
to an increased solubility in the nonpolar stationary phase. The
overall effect of lowering the pH is, thus, to drive the acidic compounds
from the mobile phase into the stationary phase with a corresponding
increase in k'. Controlling the capacity factor in this fashion is
83
often referred to as ion-suppression.
The implications of these results are fairly straightforward: 
we now have a means to adjust k' values for the acidic solutes while 
keeping k' virtually constant for the other components. A specific 
example of pH control is given in Fig. 1-14. In the chromatogram 
of Fig. 1-14A, 5-HIAA, 5-HICA, and HVA exhibit excessive retention 
times at a pH of 4.2. HVA is not shown in this diagram because 
of its extreme retention time. Increasing the pH of the mobile phase 
to 4.6 greatly reduces the overall time of analysis (Fig. 1-14B), 
while the separation of the non-acidic components remains essentially 
unchanged.
Although k.' adjustments for the amines could also theoretically 
be achieved by pH variations in the range of 8-11, this 
practice is not recommended for silica-based columns. Literature sup­
plied by the manufacturers suggests that these columns should not be 
operated with neutral or basic eluting solvents. The stationary phase 
is degraded by direct dissolution under these conditions as well as 
by chemical attack of the silyl bonds holding the alkyl group onto 
the stationary support. Therefore, alternative means had to be 
developed for manipulating the amine compounds.
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Figure 1-14. Typical Chromatograms Illustrating the Effect of the Mobile Phase pH on 
the Retention of Various Acids, Amines and Amino Acids. A pH shift from low to high values 
causes the carboxylic acids to shift from hydrophilic to hydrophobic species. Chromatographic 
conditions: 150 x 4.6 mm. Ultrasphere CDS column, flow rate =1.3 mls/min, 0.10 M citrate 
buffer. Fig. A: pH = 4.2; Fig. B: pH = 4.6. Peaks: NE (1), DA (2), 5-HTP (3), DOPAC (4),
5-HT (5), nMET (6 ), 5-HIAA (7), 5-HICA (8 ), HVA (9).
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3. Reverse Phase lon-Pairing.
lon-pairing is a chromatographic technique in which a reverse 
phase column is, in essence, transformed into an ion exchange column 
by the addition of ion-pairing agents to the mobile phase. These 
agents are typically long chain aliphatic species which have a highly 
polar ionic head group coupled to a nonpolar alkyl tail. Because of 
the extensive employment of similar compounds in detergents and cleaning 
solutionsj this technique is sometimes referred to as "soap" chromato­
graphy.
The use of the term ion-pairing to describe this technique 
is believed to be a misnomer. This expression originated from early 
attempts to describe the retention mechanism involved with ion-pairing 
agents. The formation of ion-pairs between the solute and the agent 
within the mobile phase was presumably followed by extraction of the 
neutral complex into the stationary phase (Fig. 1-15).^^’^ ^ However, 
work by Bidlingmeyer and others^^’^ ^ has produced strong evidence against 
this model. The model which currently best explains the retention mech­
anism in ion-pairing chromatography incorporates formation of a charged 
layer of lipophilic ions (ion-pair agents) on the surface of the sta­
tionary phase (Fig. 1-15B). Associated with this primary ionic layer 
is an oppositely charged layer of counterions. Solute molecules having 
a charge similar to these counterions are attracted to the surface of 
the chromatographic support where they exchange with the counterions. 
Their retention by the modified stationary phase involves a com­
bination of both electrostatic and dispersion forces. Increasing 
the concentration of ion-pairing agents in the mobile phase leads 
to an increased concentration of these agents in the stationary
s ta t i onary  phase
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Figure 1-15. Diagram Depicting Two Theories on the Retention Mechanism of Ion 
Pair Chromatography. Figure A represents the ion pair model. Figure B illustrates 
the ion interaction model proposed by Bidlingmeyer.
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phase. This increases the charge density on the surface of the 
stationary phase and the electrostatic attraction of the oppositely 
charged solutes. The opposite, although less dramatic, effect occurs 
for ionic solutes having the same charge as the ion-pairing agent. 
Electrostatic repulsion of these solutes will drive them away from 
the stationary phase, resulting in a reduction of k' values.
Common ion-pairing agents include n-alkylsulfonic acids and n-alkyl- 
quaternary ammonium salts, which are used to enhance retention of 
cations and anions, respectively.
The effect of sodium octyl sulfate (SOS) on k' values is 
shown in Figs. 1-16A and 1-16B. As can easily be seen, retention is 
greatly enhanced for the amines with increasing concentrations of SOS; 
the k' values for the amino acids are slightly increased, while those 
for the neutral and acidic metabolites are not affected or slightly 
decreased. It should be noted that this study was conducted at a 
mobile phase pH of 2.55. The acidic metabolites, exhibiting only 
slightly decreased retention times with increasing concentrations of 
SOS, would experience somewhat greater decreases at a moderately 
higher pH. The zwitterionic amino acids, on the other hand, do show 
substantial k' increases with increasing SOS concentrations. These 
compounds possess pK^ values of ca. 2.5 for deprotonation of the 
cation to form the zwitterion. Thus, a significant fraction of these 
species exist in the cationic form. At considerably higher pH values, 
they would be reconverted to the zwitterionic form almost exclusively 
and be only minimally affected by changes in SOS concentration.
The presence of SOS greatly alters the effect of pH on the amino
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Figure 1-16A. The Effect of Sodium Octyl Sulfate (SOS) on k ’ for 
Various Amines. Chromatographic conditions: 150 x 4.6mm Ultras­
phere ODS column, flow rate = 1.1 ml/min, 0.10 M citrate buffer, 
pH = 2.55, 10% methanol.
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Figure 1-16B. The Effect of Sodium Octyl Sulfate (SOS) on k' for 
Various Carboxylic Acids and Alcohols. Chromatographic conditions: 
150x4.6 mm Ultrasphere ODS column, flow rate = 1.1 ml/min, 0.10 M 
citrate buffer, pH = 2.55, 10% methanol.
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Figure 1-17. The Effect of pH on the Retention of Various Acids, Alcohols, 
Amines, and Amino Acids in Ion Pair Reverse Phase Chromatography. Chrom- 
tographic conditions: 150 x 4.6mm Ultrasphere ODS column, flow 
rate =1.3 ml/min, 0.10Mcitrate buffer, 1.28 mM 80S, 10% methanol.
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acids and amines as shown in Fig. 1-17. The added SOS causes a signi­
ficant increase in k' for the amino acids at low pH values where they 
exist as cations. Likewise, the higher pH values lead to a decrease 
in k' values for the acids since these species are shifted to their 
anionic form and, thus, repulsed by the negatively charged surface of 
the SOS-modified stationary phase.
V. CONCLUSION
Once the 'effects of these mobile phase parameters on k' values 
were established, the chromatographic conditions were varied to produce 
a rapid separation for the various catecholamine and indoleamine meta­
bolites. Our efforts proceeded in approximately the following order.
1) A pH (ca. 4.5) was selected which separated the acids 
from one another aided by the ion suppression effect. No MeOH or 
SOS was present at this point in the study. This left many of the 
amines unresolved and very close to the solvent front.
2) SOS was added to the mobile phase to provide a separation 
of the amines. Small increements (.1-3 ml) of a 0.030 M SOS solution 
were added to 2  liters of the eluting solvent until a satisfactory 
separation was achieved. This resulted in extremely long retention 
times for some of the desired compounds.
3) Methanol was added in small increments to decrease the 
total time required for each chromatogram.
4) Slight alterations of the mobile phase were performed in 
order to "fine tune" the resolution of any overlapping peaks.
A chromatogram obtained using the optimum mobile phase is 
shown in Fig. 1-18. The complete chromatographic conditions used
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Figure 1-18. Chromatogram Obtained Using the Optimal Conditions for Separating 
Various Catecholamine and Indoleamine Related Metabolites.(Note change in 
time axis at 5.0 minutes.) Chromatographic conditions: 150 x 4.6 mm 
Ultrasphere ODS column, 5 micron particle size; the mobile phase consisted 
of 0.050 M citric acid, 0.050 M sodium citrate, 7.5% methanol, pH = 4.8; 
flow rate =1.3 ml/min.
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to produce this separation were:
Mobile Phase: 0.10 M citrate buffer, pH 4.8, containing
7.5% (volume/volume basis) methanol and
0.180 nM SOS.
Flow Rate: 1.3 ml/min.
Column: 150 x 4.6 mm Ultrasphere ODS, 5 pm particle diameter.
All commercially obtained columns are not exactly the same. 
Similarly, individual columns may deteriorate with use. Adjustment 
or readjustment of the various parameters to establish the appropriate 
resolution of individual components should rely on the data presented 
in this chapter. Modifications useful in separating compounds of 
a particular type from others of the same type or a different type 
are summarized in Table 1-2.
Table 1-2. Mobile Phase Adjustments for Separating Specific Groups of Catecholamines, Indoleamines,
and Related Metabolites by Reverse Phase Liquid Chromatography
Compound
Group
Compound Group
Acids Amines Alcohols Amino Acids
Acids 1. pH change^ 
(4-5)
1. pH change^ 
(4-5)
1. pH change^ 
(4-5)
1 . pH change^ 
(2-5)
2 . ion-interaction^
c d
2 . ion-interaction ’ 2 . ion-interaction*^ 2 . pH change^ 
(2-3.5)
Amines 1 . ion-interaction*^ 1 . ion-lnteractlon*^ 1 .
2 .
ion-interac t ion
pH change^ 
(2-3.5)
Alcohols 1 . solvent strength 1 . pH change^ 
(2-3.5)
Amino
Acids
1 . pH change^ 
(2-3.5)
â bLower pH (appropriate range shown in parentheses) increases retention of acids. Lower pH (appropriate
range shown in parentheses) in combination with sulfonic acid ion-interaction agent increases retention
of amino acids. ‘^ Addition of an aliphatic quaternary ammonium salt might be useful to increase the
retention of acidic metabolites. ^Addition of aliphatic sulfonic acid increases retention of amines.
CHAPTER 2
THE DETERMINATION OF CATECHOLAMINES, INDOLEAMINES,
AND RELATED METABOLITES IN TISSUE SAMPLES
I. INTRODUCTION
The wide interest in catecholamines, indoleamines, and related 
species by neuroscientists can be directly attributed to their func­
tions as neurochemical transmitters, modulators, and hormones. Levels 
of these compounds in the body have been related to metabolic dis­
orders associated with pathological states such as neuronal tumors, 
hypertension,and certain psychic s y n d romes.The detailed involve­
ment of these compounds in the area of mental disorders is currently 
under active investigation by many groups.
The biosynthesis of catecholamines and indoleamines originates 
with the dietary amino acids tyrosine (TYR) and tryptophan (TP), as 
shown in Figs. 2-1 and 2-2. The rate limiting step in the conversion 
of these amino acids to their bioactive amine derivatives is, in both 
cases, represented by the initial hydroxylation of the aromatic ring.
The facile decarboxylation of the hydroxylated products directly yields 
dopamine (DA) and 5-hydroxytryptamine (serotonin, 5-HT), respectively. 
Subsequent side chain hydroxylation of dopamine by dopamine-g-hydroxylase 
affords norepinephrine (NE), while N-methylation of norepinephrine pro-
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TH Tyrosine Hydroxylase
DDC DOPA Decarboxylase 
MAO Monoamine Oxidase 
DBH Dopamine 3-Hydroxylase
AD Aldehyde Dehydrogenase
AR Aldehyde Reductase
PNMT Phenethanolamine-N-Methyl- 
transferase
COMT Catechol-O-Methyltransferase
Figure 2-1. Biosynthesis and Degradation of Catecholamines, The bold arrows represent primary pathways. 
Complete names for compounds shown may be found in Table 1-1. Compounds with asterisk (*) are accessible 
for quantitation by the newly proposed method (vide infra).
N-AcT „ ,  ^ ^P    N-Acetylserotonin-
HIOMT
Tryptophan TPH >  5-HTP* 5-HTPDC>  5-HT*.
MAO Aldehyde AD
AR
■> Melatonin (5-methoxy- 
N-acetyltryptamine
5-HIAA*
-> 5-HTOL*
ENZYME LEGEND
TPH Tryptophan Hydroxylase AR Aldehyde Reductase
5-HTPDC 5-Hydroxytryptophan HIOMT Hydroxyindole-O-Methyltransferase
Decarboxylase
N-AcT N-Acetyltransferase
MAO Monoamine Oxidase
AD Aldehyde Dehydrogenase
Figure 2-2. Biosynthesis and Degradation of Serotonin. Bold arrows represent primary pathways. 
Complete names for compounds shown may be found in Table 1-1. Compounds with asterisk (*) are 
accessible for quantitation by the newly proposed method (vide infra).
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vides epinephrine (EPI). These biogenic amines are catabolized by
a variety of neuronal enzymes. Oxidation of the side chain amine
group and méthoxylation of a ring hydroxyl group, however, represent
the two primary degradative pathways.
Since these amines, as well as their precursors and metabolites,
are normally found in brain tissues at only nanogram/gram or picogram/
gram levels, analytical techniques having very low detection limits
are fundamental to their quantitation. Techniques found to be adequate
for this purpose include f l u o r e s c e n c e g a s  chromatography with
97
electron capture detection, gas chromatography combined with mass
8 8  98 99
spectrometry, ’ and radiochemical methods. These techniques,
unfortunately, suffer from a lack of selectivity, the need for chemical 
derivatization, or cost requirements which are prohibitive for routine 
analyses. The combination of liquid chromatography with electro­
chemical detection (LCEC), introduced by Adams and coworkers^^'^^ 
in 1973, offered a considerable improvement in this situation. LCEC 
provided excellent selectivity through both chromatographic separation 
and the requirement for electrochemical activity at the chosen working 
electrode potential; it did not require derivatization and it was 
relatively inexpensive. Further, the electrochemical detector exhibited 
a very wide linear dynamic range^^^ and low limits of detection.
While the initially reported LCEC procedures were capable of quantitating
only a few of the compounds of i n t e r e s t , t h e y  were readily
 ^  ^  ^  ^ , 78,91-93,101-102
adopted by a variety of research groups.
The limitation of a single LCEC procedure to only a few com­
pounds, however, has recently been significantly modified by the intro-
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duction of high efficiency reverse phase columns. The reduced size 
of the microparticulate support material and improvements in packing 
techniques have almost increased the peak capacity by a factor of 
ten (c.f. Chapter 1). The dramatic improvement in separation sub­
stantially reduces the necessity for extensive sample cleanup prior 
to injection. It also markedly increases the number of compounds 
accessible for quantitation by a single procedure. Reports have al­
ready appeared which have taken advantage of these advances in LCEC.
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Thus, Mefford and Barchas ' have developed appropriate conditions
for the determination of tryptophan and a number of its metabolites,
91 93and others ’ have produced a procedure for dopamine and 
three of its metabolites.
The following, newly proposed, LCEC method permits the simul­
taneous determination of as many as eleven catecholamines, indoleamines, 
and related metabolites in as little as 10 mg of brain tissue. Only 
one chromatographic column and one eluting solvent are required for 
this procedure. Direct injection of the supernatant fraction from a 
deproteinized brain sample provides quantitation of 5-hydroxytryptophan 
(5-HTP), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), 
5-hydroxytryptophol (5-HTOL), serotonin (5-HT), and 3-methoxytyramine 
(3-MT). Following the application of a simple isolation of step to the 
remaining supemate, injection into the same column provides quantita­
tion of 3,4-dihydroxyphenylalanine (DOPA), norepinephrine (NE), 
epinephrine (EPI), 3,4-dihydroxyphenylacetic acid (DOPAC), and dopamine 
(DA).
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II. EQUIPMENT AND REAGENTS
A. Apparatus
1. Liquid Chromatographic System. The chromatographic equip­
ment and electrochemical detector have been previously described in 
Chapter 1.
2. Tissue Homogenizer. Tissue samples were homogenized 
with an ultrasonic cell disrupter, Model W-200P (Branson Ultrasonics, 
Plainview, NY), equipped with a long probe tip. This was operated
at a 50% duty cycle and a medium power setting of 6 .
3. Centrifuge. A Sorvall model RC2-B refrigerated unit 
fitted with an SM-24 rotor was used.
4. Centrifuge Tubes. Polypropylene centrifuge tubes 
(1.5 ml capacity) from KEV7 Scientific, Columbus, OH, were used for 
processing of individual samples. When subjected to centrifugation, 
the attached caps were removed by cutting with a pair of wire cutters 
so these tubes could be placed inside the standard 15 ml centrifuge 
tubes accepted by the Sorvall SM-24 rotor.
B. Animals
Adult male albino mice of the K R S HA/ICR strain were used 
as the source of tissue samples. Obtained from Gibson Laboratories 
of Madison, WI, these animals were typically 6  to 12 weeks old 
and weighed ca. 35 grams at the time of sacrifice. They were maintained 
on a 1 2  hr light/ 1 2  hr dark schedule and allowed access to food and 
water ad libitum.
C. Chromatographic Conditions
The routinely employed chromatographic conditions for this
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procedure were presented in Chapter 1. They are summarized here for 
convenience.
Mobile Phase 0.10 M citrate buffer, pH 4.8, containing
7.5% methanol (y/v) and 0.180 nM SOS.
(See below for detailed preparation.)
Flow Rate 1.3 ml/min.
Column 150 x 4.6 mm Ultrasphere ODS, 5 ym particle
diameter.
Detector Potential +0.700 V vs. SCE.
Operating Pressure typically 2200-2500 p.s.i.
D. Reagent Sources
The chemicals employed and their commercial sources have 
been described in Chapter 1.
E. Solutions
1. Stock Standard Solutions, Each stock standard solu­
tion was prepared by dissolving the appropriate amount of material
into 1 0 0 . 0  ml of previously deoxygenated double distilled water con- 
-4taining 1.0 x 10 M ascorbic acid (see Table 2-1). These solutions 
were stored at 4°C and discarded after 2—3 days.
2. Working Standard Solution. On the day of analysis,
appropriate amounts of each stock standard solution were combined and
-4
diluted to 5.00 ml with deaerated water containing 1 x 10 M ascorbic 
acid (see Table 2-2). This resulted in a solution containing the appro­
priate compounds in concentrations similar to those found in whole 
mouse brains and brain parts.
3. Internal Standard Solution. A solution containing
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Table 2-1. Preparation of Stock Standard Solutions*
Compound mg / 1 0 0  ml Compound mg/ 1 0 0  ml
NE 0.70 5-HIAA 1.30
EPI 0.75 5-HT 3.70
DOPAC 1 . 0 0 3-MT 2.50
DA 1.50 HVA 3.50
*The weights in this table refer to the commercially available form of 
the compound. For example, the entry for NE refers to 0.70 mg of nore­
pinephrine hydrochloride.
Table 2-2. Preparation of Working Standard Solutions
Compound Amount of Stock Solution Added (pi)*
Whole Brain 
and Cortex
Cerebellum Diencephalon, 
Midbrain, 
and Medulla- 
pons
Hippocampus Striatum
NE 500 1 0 0 2 0 0 1 0 0 1 0 0
EPI 25 25 25 25 25
DOPAC 250 2 0 50 25 300
DA 1 0 0 0 50 1 0 0 2 0 2500
5-HIAA 250 50 1 0 0 1 0 0 1 0 0
HVA 500 50 50 25 2 0 0
5-HT 750 1 0 0 350 1 0 0 250
3-MT 1 0 0 25 25 25 250
-4
*Final combination of stock solutions diluted to 5.00 mis with 1.0x10 M 
ascorbic acid.
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ca. 1.0 X 10  ^M DHBA and nMET was prepared by dissolving 1.60-2.00 mg 
of the commercially obtained salts of these compounds into 1 0 0 . 0  ml 
of deaerated 0.010 M HCl. 1.00 ml of this solution was then further 
diluted to 10.00 ml with the same 0.010 M HCl.
4. Mobile Phase. A buffer solution was prepared by dis­
solving 21.01 grams citric acid monohydrate (jO.OSO M), 29.41 grams tri­
sodium citrate dihydrate (0.050 M), 175 ml anhydrous, reagent grade 
methanol (7.5% v/v), 6.00 ml of 0.030 M sodium octyl sulfate (0.180 
nM) and 10.0 ml of 1.0 M sodium hydroxide in water and diluting to 2.00 
liters. The final concentration of each reagent is displayed in paren­
theses. Further sodium hydroxide was added, as necessary, to adjust 
the pH to 4.8. The final buffer was filtered through a 0.45 micron 
Millipore filter and vacuum deaerated prior to use.
5. Homogenization Solution. 6.4 ml of glacial acetic
acid (1.0 M), 4.9 grams of sodium perchlorate (0.40 M) and 2.0 grams
NaOH (0.50 M) were diluted to 100.0 ml with double distilled water,
yielding a solution with a pH of 4.80. Prior to use, this solution
78was deaerated on crushed ice for 15 min with oxygen-free nitrogen.
F. Tissue Preparation
The mice were sacrificed by cervical dislocation. The 
brains were removed as rapidly as possible, weighed, frozen by immersion 
in liquid nitrogen, and stored on dry ice. Brain parts were prepared
g
from whole brains using the dissection procedure described by Wassil.
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III. EXPERIMENTAL PROCEDURE
A. Standard Procedure for Determination of Catecholamines, Indoleamines, 
and Related Metabolites in Tissues.
The standard procedure is summarized in Fig. 2-3. Appro­
priate volumes of homogenization solution, internal standard solution, 
and ascorbic acid are initially added to individual portions of tissue 
or working standard solution to form tissue samples and standard 
samples, respectively (see Table 2-3). Typically, 3-5 standard samples 
are prepared for each separate group of tissue samples. Individual 
samples, whether tissue or standard, are subjected to ultrasonic homo­
genization, briefly mixed on a vortex mixer, and centrifuged for 30 
min at 30,000 x g and 4°C. The supernatant fraction of each sample is 
carefully transferred to a new 1.5 ml centrifuge tube and stored on 
dry ice. Any supernatant fractions which remain cloudy are centrifuged 
for an additional 15 min. Care must be exercised here to prevent in­
jection of particulate matter into the LCEC, since this will cause 
subsequent breakdown of the system. After melting the sample by 
warming in the hand, jca. 2 0  pi are injected into the chromatograph for 
quantitation of the species not containing a catechol moiety. The 
output of the LCEC is connected to both terminals of a dual pen recorder 
and settings of 5 namp and 50 namp are typically employed for full 
scale deflection.
The catechol containing compounds are determined by the pro-
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cedure previously described by Mefford et al. approximately 250 
pi of the supernatant fraction mentioned above is added to 2 0  mg of 
acid washed alumina and 500 pi of deoxygenated TRIS buffer (3.0 M,
58
SUPERNATE
ADD
ACID
WASH
ALUMINA
R A IS E  pH 
TO 8 , 6
DESORB 
CATECHOLS 
OFF OF 
ALUMINA
ADSORB
CATECHOLS
ONTO
ALUMINA
QUANTITATE
LCEC
Ultrasonic
HOMOGENIZE
Weigh brain
SACRIFICE
30 min, 27000-xg
CENTRIFUGE
HOMOGENIZATION MIXTURE 
Acetate Buffer (pH 4.8, 
1.0 M), NaC104 (0.40 M) 
DHBA (1x10-5 M), and ~  
nMET (1x10-5 M)
Figure 2-3. Flow Chart for Determination of Catecholamines, 
Indoleamines, and Related Metabolites in Brain Tissue.
Table 2-3. Preparation of Tissue and Standard Samples
Solution Amount Added to Individual Samples, pi
Tissue Samples Standard Samples
Whole Brain 
or 
Cortex
Other Brain 
Parts®
Whole 
Brain or 
Cortex
Other
Brain Parts
Internal Standard 2 0 0 50 2 0 0 50
Working Standard -- -- 1 0 0 50
Homogenization Solution 750 250 750 250
-4Ascorbic Acid, 1.0 x 10 i 1 0 0 50 350 50
L n
V O
Refers to all brain parts except cortex.
Added to compensate for the working standard solution used in standard samples and the brain tissue 
used in tissue samples.
60
pH 8 .6 ). After shaking for 15 min, the alumina is allowed to settle. 
The liquid is carefully aspirated by suction with a disposable pipet 
having a finely drawn tip. Care should be taken to remove as much 
liquid as possible without removing any of the very small alumina par­
ticles. The alumina is washed once with a 250 pi aliquot of TRIS (6.0 
mM, pH 8 .6 ) and once with a 250 pi aliquot of water. Both washings 
are followed by aspiration. After the final wash, the catechols are 
desorbed by addition of 200 pi of 0.20 M HCIO^ and brief mixing on a 
vortex mixer. Finally, after light centrifugation(1000xg, 5 min), 
ca. 20 pi of the supernate is injected into the LCEC for quantitation 
of the catechol species. Again, recorder settings of 5 and 50 namp 
are typically employed.
Calculations of the results for individual compounds are 
analogous to those previously reported by Sasa and Blank:
/ / tissue , ,ng compound in std^
where
_ .peak height of compound in tissue sample % 
tissue peak height of internal std in tissue sample
.peak height of compound in standard sample \ 
std,ave peak height of internal std in standard sample ave
The internal standard is nMET for all the compounds determined by direct 
injection of the original supernatant (5-HIAA, HVA, 5-HTOL, 5-HT, and 
3-MT), while DHBA serves as the internal standard for the catechols 
(DOPA, NE, DOPAC, and DA). All results for multiple determinations
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are expressed as the mean ± the standard error of the mean (SEM). 
Statistical comparisons were performed by use of the Student t-dis- 
tribution.^
B. Determination of Per Cent Recovery of Individual Compounds from 
Tissue Samples
The per cent recovery of individual components was ob­
tained by subtracting the results for tissue homogenates from those 
for similar samples with a standard addition and comparing the result 
to untreated standard samples. The absolute per cent recovery focused 
on the peak heights obtained for the individual components only, while 
the relative per cent recovery examined the ratio of the peak heights 
of the desired components to the appropriate internal standards.
The three sample groups for the employed procedure were 
labelled according to their composition: brain homogenate CBH),
brain homogenate plus standard addition (BHP), and no brain homogenate 
(NB). A pooled homogenate was prepared by adding three whole mouse 
brains to 750 pi of homogenization solution in a 15 ml polypropylene 
centrifuge tube. Following sonication for 10 sec, a further 1.50 ml 
of homogenization solution were added and the mixture was again 
sonicated until homogeneous. Aliquots of the homogenate were immedi­
ately dispensed into prelabeled, individual sample tubes according 
to Table 2-4. After adding the remaining solutions, the sample tubes 
were briefly mixed on a vortex mixer. Those samples containing brain 
homogenates (BH and BHP) were subjected to the standard procedure 
outlined above in Section III.A.
The per cent recoveries of 5-HIAA, 5-HT and 3-MT were
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Table 2-4. Preparation of Samples for Determination of Per Cent 
Recoveries.
Solution Amount Added to Individual Samples, pi
Sample Type
BH BHP NB
Brain Homogenate 250 250 —
Ascorbic Acid^ 50 - 250
Working Standard^ - 50 50
Internal Standard^ 50 50 50
Total Volume 350 350 350
^The ascorbic acid (1x10  ^M) substitutes for brain homogenate in NB
samples and for working standard in BH samples.
*"See sections II.D.2 and II.D.3 above.
separately calculated as:
Absolute Recovery (%)
_ (peak height cmpd in BHP sample-peak height cmpd in BH sample) 
(peak height compd in NB sample)
Relative Recovery (%) = ---  xlOO
^ B
where
_ peak height of compd in BHP sample____________
bHP peak height of internal std in same BHP sample
„ _ peak height of cmpd in BH sample_____________
bH peak height of internal std in same BH sample
_ _ peak height of cmpd in NB sample_____________
nB peak height of internal std in same NB sample
The per cent recoveries for catechol containing compounds also
employed the standard procedure outlined in Section III.A. However, the
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determination of absolute recoveries for these species requires that 
the volume of original supernatant fraction taken for alumina isolation 
must be carefully controlled at 250 pi rather than using the usual 
approximation of this quantity. Since desorption from alumina uses only 
100 pi of acid eluent, the calculations of absolute recoveries must 
be slightly modified from that outlined above. This is accomplished 
by multiplying the results by (100/250); otherwise, the calculations 
are exactly as presented. It should also be noted that injection 
volumes are assumed to be constant throughout these determinations; 
appropriate corrections are required if this is not the case.
During the development of the standard procedure, a solvent 
extraction was investigated as a possible single step isolation pro­
cedure for acidic metabolites. For these studies, a 250 pi aliquot of 
buffer tartrate or acetate), brain homogenate, or brain homogenate 
with standard addition was thoroughly shaken with 500 pi of a nonaqueous 
extraction solvent for 15 min. A 250 pi aliquot of the extraction sol­
vent was placed in a small vial and blown dry with a stream of nitrogen. 
The residue was taken up in 250 pi of water and 10 pi of this solution 
was injected into the chromatograph. The absolute per cent recoveries 
of individual compounds were determined by directly comparing the dif­
ference in peak heights obtained from the two types of brain homo— 
genate samples to those from a 5 pi injection of the original, unex­
tracted buffer solution.
IV. RESULTS AND DISCUSSION
A. Preliminary Studies with Low Resolution Chromatograph
Our initial efforts in the area of multicomponent deter­
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minations were, in fact, only concerned with three acidic metabolites,
i.e., DOPAC, HVA, and 5-HIAA. Using a hand-packed column containing 
a large particle diameter anion exchange resin (DuPont Zipax SAX), 
we incorporated 5-hydroxyindole-3-carboxylic acid (5-HICA) as an 
internal standard. A typical chromatogram of a simple aqueous solu­
tion of these four compounds is shown in Fig. 2-4A. The resulting 
peaks are quite broad and the separation affords only marginal resolu­
tion (R = 1.05) for 5-HIAA and 5-HICA. The separation proved to be 
even less desirable when acidified, centrifuged supernatant fractions 
of brain homogenates were employed as shown in Fig. 2-4B. The very 
large 'solvent' peak almost totally obscured the HVA and DOPAC in these 
samples. Determination of whole mouse brain 5-HIAA yielded a typical 
value of 427±47 ng/g, although the severely sloping baseline under the 
5-HIAA peak makes these results somewhat questionable.
Attempts at eliminating the rather substantial 'solvent' peak 
were undertaken to improve the results. We, thus, focused our attention 
on a simple isolation step requiring only extraction of the brain 
homogenate with a non-aqueous solvent. The compounds would be recovered 
from the non-aqueous solvent by taking this solution to dryness and 
then reconstituting in an aqueous buffer for injection into the LCEC, 
Initial studies employed only standard solutions of the compounds in 
a 0.50 M phosphate buffers. Since these compounds and related species 
were known to have pK^ values around 4.5, a pH of 4.1 was selected to 
maintain the acids in their protonated, uncharged forms. As can be 
seen in Table 2-5, ethyl acetate yielded the best results and this 
solvent was used in all subsequent experiments.
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Figure 2-4. Typical Chromatograms Obtained from Zipax SAX Resin. Fig. A illustrates the low 
resolution separation of acidic compounds from an aqueous standard solution. Fig. B was obtained 
by injecting an acidic extract of brain tissue. Peaks are: HVA (1), DOPAC (2), 5-HICA (3), 5-HIAA (4) 
Chromatographic conditions: acetate buffer (0.080 M), pH = 5.0; flow rate = 1.7 ml/min.
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Table 2-5. Absolute Per Cent Recovery of Acid Metabolites from Tartrate 
Buffer Using Various Extraction Solvents
Extraction Solvent Absolute Per Cent Recovery
DOPAC 5-HIAA HVA 5-HICA
Ethyl acetate 52 42 64 1 0 2
Chloroform 25 1 . 2 8.9 2.9
Ethyl ether 24 29 37 55
Benzene 0 0 3.0 0
Carbon tetrachloride 0 0 0 0
Dichloroethane 0 0 0 0
Heptane 0 0 0 5.7
Toluene 0 0 0 0
Since the pH value of 4.1 was rather arbitrary, the affect 
of pH on the extraction was examined more closely. As seen in Fig. 2-5, 
the per cent recovery for the three endogenous components was highly 
dependent on the pH of the aqueous media. A fixed value between 4.0 
and 4.5, however, would appear to provide an acceptable recovery for 
all the compounds of concern.
But, buffering tissue homogenates to a constant pH proved to 
be an impossible task. The homogenates were prepared by sonicating a mix­
ture of brain tissue with 1.0 M HCl which was prepared by adding 1.0 ml
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Figure 2-5. Absolute Per Cent Recovery for Various Acid Metabolites 
as a Function of the pH of the Extracted Medium. The solution extracted 
contained 0.50 M phosphate buffer for pH control. The extracting 
solvent was ethyl acetate.
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of acid per 1.0 g of tissue. 250 pi of the supernatant fraction from 
the centrifuged homogenate was mixed with 100 to 1500 yl of a saturated 
solution of sodium tartrate (ca. 1 . 0  M) for extraction with ethyl 
acetate. However, the resulting aqueous mixture exhibited pH fluctua­
tions as great as ±0.5 for individual samples. Similar results were 
obtained when acetate buffers of various pH values and molarities 
were attempted.
The dramatic success reported for the separation of biogenic
amines and related species using high resolution.columns about this 
91 93time, ’ as well as the difficulties encountered in the above approach, 
caused us to abandon our attempts at solvent extraction coupled with 
separation by the strong anion exchange resins. Instead, we began to 
investigate the use of reverse phase chromatography to provide the 
determination of the originally desired compounds and many others at 
the same time.
B. Determinations Employing Reverse Phase Chromatography.
The development of appropriate chromatographic conditions for 
the high efficiency, reverse phase separation of catecholamines, indole­
amines, and related metabolites has been covered in Chapter 1. Using the 
derived conditions, simple injection of the supernate from an acid homo­
genized, centrifuged tissue sample leads to a result similar to that pre­
sented in Fig. 2-6 for mouse brain striatum. The 'solvent' front 
noticeably trails into the chromatogram for the first 5 minutes or 
so. This makes quantitation of the more rapidly eluting components 
difficult at best. Fortunately, however, most of these species contain 
a catechol group in their structure. Thus, we originally attempted
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Figure 2-6. Typical Chromatogram of Mouse Striatum Direct 
Injection of Centrifugate. Mobile phase: 0.10 M citrate buffer, 
pH 4.8, containing 7.5% methanol and 0.18 mM sodium octyl sulfate. 
Flow rate = 1.3 ml/min. Peaks are: 5-HIAA (1), HVA (2), 5-HT (3), 
3-MT (4), nMET (5).
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to employ direct injection of the homogenate supemate only for 
quantitation of those compounds eluting after dopamine (t^ = 4  min); 
the remaining supernatant fraction would be subjected to a standard 
catechol isolation on a l u m i n a ^ w i t h  subsequent injection of 
the alumina eluate into the same LCEC for determination of the earlier 
eluting species. As shown in Fig. 2-7, the alumina step leads to 
a substantially decreased 'solvent' front with a corresponding increase 
in the ease of quantitating the catechols.
The procedure originally used here was virtually identical 
to that described in Section III.A, the only difference being that 
0.10 M HCIO^ was used as the homogenization medium. While this is a 
relatively straightforward procedure, we wanted to make sure it was 
appropriate for general application before subjecting it to routine 
utilization. Thus, we proceeded to examine the linear dynamic range, 
detection limits, possible interferences, and composition of the 
homogenization solution before employing it with typical tissue samples.
1. Linear Dynamic Range and Detection Limits. Solutions 
containing various amounts of the compounds of interest and a fixed 
amount of the internal standards, DHBA and nMET, were prepared for in­
jection into the LCEC. The concentrations were selected to adequately 
cover those expected from the analysis of typical tissue samples.
A linear regression of the plots of peak height ratio (peak height 
of the compound of interest/peak height of the internal standard) vs. 
the concentration produced correlation coefficients very close to 
1.00 for all the compounds investigated (see Table 2-6), Detection 
limits for the individual compounds, defined as the amounts which pro-
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MINUTES
Figure 2-7. Chromatogram of Sample from Fig. 2-6 after Alumina 
Isolation of Catechols. Chromatographic conditions: see Fig. 2-6. 
Peaks are: NE (1), EPI (2), DHBA (3), DOPAC (4), DA (5).
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Table 2-6. Linear Dynamic Range and Limits of Detection for Various 
Compounds Determined by Reverse Phase LCEC Procedure.
Compound Internal Standard Range (pmol) Correlation Coefficient
NE DHBA 0.05-200 1 . 0 0
EPI DHBA 0.10-150 1 . 0 0
DOPAC DHBA 0 .1 0 - 2 0 0 0.998
DA DHBA 0.07-350 1 . 0 0
5-HIAA nMET 0.15-250 1 , 0 0
HVA nMET 0.40-500 1 . 0 0
5-HT nMET 0.10-300 1 . 0 0
3-MT nMET 0.040-500 0.997
TYR DHBA 50-50,000 1 , 0 0
TP nMET 150-50,000 1 . 0 0
DOPA DHBA 0.05-100 1 . 0 0
5-HTP nMET 0.10-150 1 . 0 0
5-HTOL nMET 0.15-300 0.999
duced peak heights twice the level of baseline noise, are also repre­
sented in Table 2-6 as the lower value of the range investigated,
2. Possible Interferences. While the electrochemical detector 
adds a great deal of selectivity to this procedure, complete 
assurance of peak purity is certainly not guaranteed by employment of 
LCEC. Thus, we decided to investigate the chromatographic and electro-
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chemical characteristics of a number of compounds which might interfere 
with this technique. Further proof of peak identity is provided later 
by the agreement between tissue results obtained using LCEC and alterna­
tive techniques (vide infra). The capacity factors and peak potentials 
for species which might interfere as well as the compounds of interest 
are presented in Table 2-7.
3. Homogenization Solution. The homogenization solution repre­
sents virtually the only parameter which should effect the per cent 
recoveries for individual components. We initially anticipated that 
this parameter would have only a minimal effect on the results. In 
fact, we expected 1 0 0 % absolute recoveries for, especially, the com­
ponents determined by direct injection. Using classical precipitating 
reagents, i.e., HCIO^ and HCl, however, we were surprised to find some 
recoveries to be well below 100%. This is exhibited in the evaluation 
of the relative per cent recoveries presented in the first three 
columns of Table 2-8. This result was most notable for the acidic 
metabolites, 5-HIAA and HVA. These compounds are neutral, relatively 
hydrophobic species at low pH, possibly leading to strong interactions 
with the more hydrophobic components of the centrifugal pellet. Thus, 
we decided to increase the pH of the homogenization solution above 
the pK^ values for these acids. We also decreased the polarity of 
the homogenization solution by employing organic acids in place of 
the mineral acids. Perchlorate anion, as NaClO^, was added to aid 
in macromolecular precipitation. The results, shown in the last three 
columns of Table 2-8, exhibit an adequate yield of the desired compounds 
using either acetate or proprionate buffers. Similar results are
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Table 2-7, Capacity Factors and Voltanmetric Peak Potentials for Catechol­
amines, Indoleamines, Metabolites, and Possible Interfering Species
Compound k'^ Ep^
(Volts vs. SCE)
Vanillylmandelic acid (VMA) 0.28 0.64
3,4-Dihydroxyphenylalanine (DOPA) 0.52 0.51
3,4-Dihydroxyphenethylglycol (DOPEG) 0.80 0.54
Norepinephrine (NE) 0.85 0.61
Tyrosine (TYR) 0.93 0.81
Epinephrine (EPI) 1.4 0.57
3,4-Dihydroxyb enzylamine (DHBA) 2 . 1 0,38
3-Methoxy-4-hydroxyphenethylglycol (MOPEG) 2 . 1 0 , 6 8
5-Hydroxytryptophan (5-HTP) 2 . 2 0,50
Normet anephrine (NORMET) 2.3 0,64
3,4-Dihydroxyphenylacetic acid (DOPAC) 2.9 0.50
3,4-Dihydroxyphenethylamine (DA) 3,8 0.51
Metanephrine (MET) 4,2 0,70.
5-Hydroxyindoleacetic acid (5-HIAA) 7,3 0,48
Tryptophan (TP) 7.5 0,89
Homovanillic acid (HVA) 9.7 0.62
5-Hydroxytryptophol (5-HTOL) 11,4 0,47
5-Hydroxytryptamine (5-HT) 1 2 , 6 0.50
3-Methoxytyramine (3-MT) 13.1 0.64
5-Hydroxy-N^-methyltryptamine (nMET) 16.0 0.50
N-Acetyl-5-Hydroxytryptamine (N-Ac-5-HT) 2 0 . 1 0.43
5-Methoxytryptamine (5-MT) 40.0 0.78
Melatonin (MEL) 40.0 0.75
^k' = (tr-tg)/to where t^ is the retention time of the compound of in­
terest and tg is the retention time of an unretained compound.
^Determined at a carbon paste electrode using the chromatographic mobile
phase as the electrochemical solvent.
Table 2-8. Per Cent Relative Recoveries Obtained Using Various Homogenizing Solutions.*
Compound
Homogenization Medium
0.090 M 
HCIO^
0.44 M 
HCIO^
1.0 M 
HCl
1.0 M Formate 
Buffer with 
0.40 M NaClO, 
(pH = 2.4)
1.0 M Acetate 
Buffer with 
0.40 M NaClO, 
(pH = 4.8)
1.0 M Pro­
pionate 
Buffer with 
0.40 M 
NaClO,
(pH = 4.6)
NE 1 0 1 95 104+13 1 0 0 10614 11315
EPI 90 1 1 0 95+4 98 9813 10913
DOPAC 118 1 2 0 1 2 0 1 1 0 150 190116^ 15119
DA 103 1 0 2 9615 95 10515 1 1 0 1 2
5-HIAA 60 75 6 6 l6 74 9012 9412
HVA 78 77 8711 98 11013 10214
5-HT 93 92 10013 96 9712 10615
3-MT 59 54 9713 108 91110 10213
Ln
Results are presented as mean +S.D. for the average values taken from three separate experiments. Each 
experimental average was derived from five individual determinations.
This value becomes 97±8 if one corrects for the absolute recovery of DOPAC in the presence vs. the 
absence of brain tissue (see Table 2-10).
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found through the calculations of the absolute per cent recoveries,
as presented in Table 2-9. The absolute per cent recoveries obtained
using either acetate or propionate approach 1 0 0 % for the directly
injected species. Since acetate is generally more readily available,
it was adopted for all routine investigations. The values of ''<60%
for the compounds isolated on alumina are completely comparable to
those obtained by others. The only exception to this, i.e., the
poor recovery of DOPAC from alumina, is not understood. However,
other investigators have reported similar anomolous behavior with 
93
DOPAC. Also disturbing is the fact that the absolute per cent re­
covery for DOPAC is greater in the presence of brain tissue than in 
the absence of brain tissue as shown in Table 2-10. Although this 
result cannot currently be explained, the final results for all brain 
samples were corrected to account for this by dividing the normally 
obtained answer by 0.51.
Table 2-10. Per Cent Absolute Recovery of DOPAC in Presence and Absence 
of Brain Tissue.^
With Tissue Without Tissue
% Recovery 33±3 16±4
homogenization medium was 1.0 M acetate buffer with 0.40 M NaClO^
(pH = 4.8)
Table 2-9. Per Cent Absolute Recoveries Obtained Using Various Homogenizing Solutions.'
Compound
Homogenization Medium
1.0 M Formate Buffer 
with 0.40 M NaClO ' 
(pH 2.4) 1.0 M HCl
1.0 M Acetate Buffer 
with 0.40 M NaClO, 
(pH 4.8) 4
1.0 M Proprionate 
Buffer with 0.40 
M NaClO^ (pH 4.6)
ne’’ — 70 63+4 -
EPI^ — 70 59±6 -
DHBA^ — 65 61+2 -
DOPAC^ — 35 32±6 -
DA^ — 6 6 62±2 *—
5-HIAA 76 67 95+5 83
HVA 98 94 106±6 92
5-HT 92 104 92±2 92
3-MT 113 95 97±22 93
nMET 98 105 92±9 103
Results presented as mean ±S.D. for the average values taken from three separate experiments. Each 
experimental average was derived from five individual determinations.
Results obtained following alumina isolation.
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4. Analysis of Mouse Brains. Having developed and refined 
the procedure, we proceeded to employ it in the determination of the 
catecholamines, indoleamines, and related metabolites in tissue samples. 
The results are presented in Table 2-11. Although the chromatographic 
conditions are capable of separating many more species than those 
quantitated (see Section IV.B.3), such species are present, unfortunately, 
at levels below the detection limits of the current configuration. 
Likewise, some of the more difficult to oxidize compounds, like TYR 
and TP, were selectively ignored through the use of a moderate working 
electrode potential (+0.700 V vs. SCE). Nonetheless, we were capable 
of determining eight compounds in all or most of the eight different 
brain regions examined. This is a substantial improvement over previous 
procedures which could quantitate only one to, at most, four of these 
compounds on a routine basis.
Comparison of the currently obtained results to those previously 
reported by others is provided in Table 2-12. Since results for mica 
are relatively uncommon, we have taken the liberty of including some 
data for rats. In general, the current results are quite comparable 
to those previously reported.
To further demonstrate the applicability of the final procedure, 
we undertook a pharmacological investigation. One group of mice (expéri­
mentais) was injected with 500 yl of a pargyline solution, i.p., con­
taining 1.0 mg/ml of the hydrochloride salt in isotonic saline (0.90% 
NaCl). A second group (controls) was injected with 500 yl of the iso­
tonic saline only. Both groups were sacrificed 90 minutes later.
The brains were removed and subjected to the described procedure.
Table 2-11. Tissue Content of Catecholamines, Indoleamines and Related Metabolites in Different 
Regions of Mouse Brain.&
Region Content, ng/g
Average Weight 
of Region (mg)
NE EPI DOPAC DA 5-HIAA HVA 5-HT 3-MT
Cerebellum 54±4 173+25 — — — 130110 —— 8518 -
Medulla-Pons 37+2 392+14 14+3 1515 66+3 550+18 - 690+23 -
Midbrain 38±11 445+26 - 3213 6616 935135 180110 870173 77110
Diencephalon 63+1 494124 17+4 113123 4341105 797+16 321123 835161 97112
Hippocampus 30+3 358126 911 1 1 1 1 56117 444127 - 66017 -
Striatum 41+4 116111 — 41614 76911423 495123 1132123 73217 17321110
Cortex 13517 242113 — 76113 452120 327145 197116 613135 -
Whole Brain 450+28 386129 — 113145 11741109 401153 266154 767+89 2391108
Whole Brain 
(reconstructed 
from regional 
results)^
302 3.6 98 1031 480 251 717 2 0 1
Results expressed as meaniSEM for at least five separate determinations.
The reconstructed whole brain results were calculated by summing the product of the regional result times 
the average weight of that region for all regions.
Table 2-12. Comparison of Reported Values for Various Catecholamines, Indoleamines, and Related
Metabolites in Rat and Mouse Brain Tissues
Whole
Reported Value (ng/g±SEM)
Brain
or
Brain
Tissue NE EPI DOPAC DA 5-HIAA HVA 5-HT 3-MT
Animal
Type Method^ Reference
whole
brain
— — - — 526±81 - 526±81 — rat GCMS 69
whole
brain
— — - 973+16 — —— 805±12 — mouse GCMS 1 0 1
whole
brain
— — - — 294±7 - 238±19 — rat LCEC 69
whole
brain
— — - — 253±26 106±17 —— — mouse FLUOR 109
whole
brain
380+16 — - 843+16 525±36 464±32 — rat FLUOR 90
whole
brain
386±13 113±26 1174±50 401±50 266±25 761±40 239±25 mouse LCEC this
report
cere­
bellum
296±14 — - 28 ±4 - - 103 ± 8 — mouse LCEC 67
cere­
bellum
2 0 0 ± 1 0 — <50 100±30 < 2 0 rat FLUOR 85
cere­
bellum
190±18 —— — 29±9 144 ± 6 78±15 rat FLUOR 90
cere­
bellum
256±7 .58±.08 — 8 ± 1 —— rat FLUOR 107
cere­
bellum
173 ±25 — 130±10 85 ± 8 mouse LCEC this
report
00o
Table 2-12 (continued)
Whole
Reported Value (ng/g±SEM)
Brain
or
Brain
Tissue NE EPI DOPAC DA 5-HIAA HVA 5-HT 3-MT
Animal
Type Method^ Reference
striatum 19501130 690160 rat LCEC 92
striatum 153+13 — 4777+380 —  — 579125 ---- mouse LCEC 67
striatum 380+100 — 840+70 8300+420 630150 — ---- rat FLUOR 85
striatum 116±11 47614 76911423 495123 1132123 73217 mouse LCEC this
report
Methods utilized are gas chromatography/mass spectrometry (GCMS), fluorescence (FLUOR), and liquid 
chromatography with electrochemical detection (LCEC).
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Since pargyline is a well known blocking agent for monoamine oxidase 
(MAO), one would expect the treated animals to show increased levels 
of amines and decreased levels of their acid metabolites. As shown 
in Fig. 2-8, this is precisely what was observed. The fact that no 
abnormalities were observed for the treated samples also adds credence 
to the original assignment of peaks.
V. COMMON OPERATIONAL PROBLEMS
Prolonged application of the outlined procedure has demon­
strated the occurrence of two rather distinctive problems: column
plugging and loss of resolution.
A. Column Plugging.
The direct injection of centrifuged, homogenized brain 
supernatant material into the LCEC will eventually lead to clogging 
of the column inlet. This is due to the incomplete removal of par­
ticulate matter by this rather simple isolation step. Although such 
clogging requires a considerable increase in operating pressure, it 
does not usually alter the observed resolution of individual components. 
This situation can generally be remedied by simply replacing the 2 ym 
inlet end frit with a new unit. Attempts at cleaning the old frit 
have generally proved ineffective. If the particulate matter has 
penetrated into the top of the packing material, it may also be necessary 
to replace the top 2 mm or so with new packing m a t e r i a l . I f  this 
is required, the reassembled column should be briefly subjected to 
normal operation, i.e., pumping the eluting solvent through the column, 
for about 5 min. It should then be taken apart again to fill any re-
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Figure 2-8. The Effect of Pargyline on Catecholamines, Indole­
amines, and Related Metabolites in Mouse Striatum and Diencephalon. 
Mice were injected with pargyline-HCl in saline (150 mg/kg, i.p.), 
and were sacrificed 1 1/2 hrs after treatment. i -i Striatum 
Diencephalon.
% change =
treated - control 
control
X 100
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suiting voids at the top of the column. The repaired column should 
exhibit only minor losses in resolution with an operating pressure 
near that of a new column.
Clogging can be substantially decreased by filtering the sample 
prior to injection in the LCEC. Our laboratory now routinely utilizes 
filtration for all tissue homogenates.
B. Resolution Problems.
Injection of multiple samples into any liquid chromato­
graph and/or simple aging of the system will almost certainly lead 
to a loss in resolution. Likewise, one may be interested in modifying 
the conditions to focus on metabolites not included in the current 
procedure. If either of these situations should occur, there are three 
major alternatives available to the analyst. These are (1) alteration 
of the mobile phase, (2 ) adjustment of the electrode potential, and 
(3) installation of a new column. However, we would suggest the analyst 
carefully examine which solutes are essential for the particular 
experiment at hand before attempting any of these alternatives. A 
judicious choice will allow systematic investigations rather than the 
usually employed, and ultimately frustrating, trial and error approach.
Mobile phase parameters to be considered include pH, ionic 
strength, solvent strength, and ion-pairing a g e n t s . T h e s e  
shouJ.d all be considered for compounds not accessible by the current pro­
cedure. Also, in the current procedure, a loss of resolution can lead 
to a deterioration in the separation of, especially, 5-HT and S-^ MT.
An increase in the mobile phase concentration of the ion-pairing agent, 
sodium octyl sulfate (SOS), should provide improvement in such cases
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(c.f. Fig. 1-16), although this solution may also require longer times 
for individual chromatograms.
The selection of the electrode potential is a very pertinent 
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parameter to be considered. ’ ’ Thus, if the peak potential (c.f.
Table 2-6) of an undesirable component is at least 0.10 volt greater 
than the compounds to be determined, the former can typically be 'tuned 
out.' This alternative may also be applied to the routine determination 
described above. Thus, if a deteriorating column exhibits a poor separa­
tion for 5-HT and 3-MT, one may decide that the 3-MT information is 
not essential. Selecting a working electrode potential of +0.52 to
0.60 volt vs. SCE, the analyst would be able to quantitate 5-HT (E^ = 
+0.50 V) while 3-MT (E^ = +0.64 V) would pass through the detector 
virtually unnoticed.
Replacement of the column is, of course, always available to 
the analyst as an alternative. However, the cost of new columns gen­
erally makes this the last choice to be considered. For the determina­
tion of compounds other than those which are the subject of the current 
procedure, one should also consider the possible use of different packing 
materials.
VI. CONCLUSION
The currently employed procedure for the determination of 
catecholamines, indoleamines, and related metabolites is relatively 
simple, inexpensive, and rapid. Approximately 25 samples may be pro­
cessed with this procedure by a trained analyst in a single day. Even 
faster throughput is available if one employs an automatic sample
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injection device and computer controlled data acquisition/manipulation. 
Tissue samples as small as 1 mg may be analyzed, although brain tissue 
samples of > 2 0  mg are typically required to provide adequate data 
for the majority of compounds of interest. Only minor modifications 
in the sample volume and preparation would allow the direct applica­
tion of the described procedure to the analysis of biological fluids 
such as blood, serum, cerebrospinal fluid, or urine.
Since the current procedure is capable of quantitating a 
large number of compounds under simple isocratic conditions, the 
necessity for multiple chromatographic setups or multiple eluting 
solvents has been effectively eliminated. The system employed is 
also capable of quantitating virtually all the products of the primary 
enzymatic reactions involved in the biosynthesis and degradation 
of catecholamines and indoleamines. This expands the capability of 
the system to include its utilization in routine determinations of 
enzyme activities. Indeed, our laboratory is currently using the 
described LCEC conditions for the assay of tyrosine hydroxylase, DOPA 
decarboxylase, 5-hydroxytryptophan decarboxylase and monoamine oxidase.
CHAPTER 3
MONOAMINE OXIDASE - A GENERAL INTRODUCTION
I. INTRODUCTION
The previous two chapters have discussed the chromatographic 
separation and quantitation of low level concentrations of tyrosine 
and tryptophan metabolites in mouse brain tissue. In the following 
chapter, these chromatographic principles are applied to the quantitation 
of the enzymatic degradation products of biogenic amines by monoamine 
oxidase (MAO).
Monoamine oxidase [monoamine;oxygen oxidoreductase (deaminating), 
EC 1.4.3.4] is of considerable physiological importance in the brain, 
since it catalyzes the inactivation of neurochemical transmitters such 
as dopamine, serotonin and norepinephrine. Monoamine oxidase (MAO) 
promotes the oxidative deamination of monoamines according to the 
following reaction:
R-CH^NHg + O2  + H^O-^RCHO + HgOg + NH^
The initial product from deamination of an amine is an aldehyde. This, 
in turn, can be converted by aldehyde dehydrogenase (AD) to the cor­
responding acid (Fig. 3-1). The aldehyde intermediate may also be 
reduced to form an alcohol by aldehyde reductase (AR).
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Figure 3-1. Metabolic Pathway of Primary Amines in Brain Tissue.
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The amount of product produced by MAO-AD coupled systems (nmol/ 
mg tissue/min) is an empirical value which directly represents the concen­
tration of this enzyme in the examined tissue. The development of the
analytical procedure for MAO is preceded, in this chapter, with a dis­
cussion of the biological properties of the enzyme and the previously 
employed methodology used to assess its activity.
Over the past thirty years, MAO has received considerable
39attention. It has been implicated in mental depression and schizo- 
phrenia^^’^ ^ for several years. Pharmacological interest in MAO is 
widespread due to the efficiacy of certain compounds which inhibit MAO 
in combating some forms of mental depression. Increased levels of
serum MAO have also been reported in patients with chronic heart
52 53 54 55
failure, liver conditions, diabetes mellitus and hepatic fibrosis.
An extensive review of the biochemical and pharmacological properties
44
of this enzyme is presented in the work of Costa et al.
MAO is one of two enzymes that are primarily responsible 
for the degradation of catecholamines in neuronal tissue, the other 
being catechol-O-methyltransferase. It is generally nonspecific and 
will act on many monoamines, including the methoxylated metabolites 
3-0-methyldopamine (also known as 3-methoxytyramine or 3-MT) and 
normetanephrine (NOSMET). Measurements of MAO activity have employed 
a wide variety of primary amines as substrates.
II. Characterization and Distribution of Monoamine Oxidase
Two forms of the enzyme have been tentatively identified in 
rat brain tissue.These isozymes have been classified as MAO A and 
MAO B. This classification is based both on ^  vitro substrate 
specificity and inhibitor selectivity. Table 3-1 characterizes some
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Table 3-1. Characterization of Monoamines as Substrates for Type A 
and Type B MAO^
Type A Type A + B Type B
5-hydroxytryptamine p-tyramine beta-phenethylamine
(5-HT)
m-tyramine
(low concentration)
5-methoxytryptamine phenethanolamine
(5-MT) dopamine (DA) (low concentration)
epinephrine (EPI) p-octopamine 0 -tyramine
norepinephrine (NE) tyramine 1,4-methylhistamine
metanephrine (MET) m-octopamine
normetanephrine beta-phenethylamine
(NORMET) (high concentration)
phenethanolamine 
(high concentration)
Data obtained from ref. 33.
biogenic amines as type A, type B, or Type A+B substrates. The MAO 
inhibitors commonly used for classifying substrates are clorgyline, which 
preferentially inhibits the A form and deprenyl, which preferentially 
inhibits the B form. These compounds are basically acetylenic 
amines as shown on the next page. A third compound, pargyline, is 
reported to be MAO B specific,however it is neither as specific nor 
as commonly employed as deprenyl for MAO B inhibition. Typical inhibition 
curves are reproduced in Figs. 3-2A and 3-2B as an illustration of how 
the isozymes are classified.The two curves show type A (Fig. 3-2A)
91
Z
O
3 4 5 6 7 
-LOG (INHIBITOR) (M)
8 10
Figure 3-2A. The Effect of Deprenyl Inhibition on the Oxidation of 
Biogenic Amines. Substrate: 5-HT (,o) , DA (*), and beta-phenethylamine
(+). Data from reference 33.
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Figure 3-2B. The Effect of Clorgyline Inhibition on the Oxidation of 
Biogenic Amines by MAO. Substrates: 5-HT (o), DA(*), and beta-phenethyl­
amine (+). Data from reference 33.
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and type B (Fig. 3-2B) inhibition of serotonin, a type A substrate, 
phenethylamine, a type B substrate, and dopamine, a substrate for both 
types A and B, Substrates for both types A and B are typically re­
cognized by a biphasic titration curve as seen for dopamine. Although 
most experts in the field accept the isozyme concept of MAO, many un­
answered questions concerning the multiple forms of MAO still remain. 
Reference 33 is recommended as an excellent introduction to the large 
amount of work being done on MAO characterization.
Purification of the individual isozymes has not been accom-
46plished; however, multiple attempts have been reported. Recently, 
kinetic studies using several different substrates and inhibitors haye 
additionally indicated that type B may be heterogeneous in rat liver, 
human blood platelets and pig h e a r t . I n v e s t i g a t o r s  studying oxygen, 
a natural MAO cosubstrate, have also concluded that a simple binary
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classification of MAO is an oversimplification.^^ These results muddle 
an already confusing picture concerning the existence of multiple 
forms of MAO.
For the most part, the subcellular localization of MAO in brain
is in the outer membrane of mitochondria. The MAO which is primarily
concerned with catecholamine and indoleamine degradation is presumed to be 
located in mitochondria found in the presynaptic nerve ending. In 
normally functioning neurons, the transmitter is released by electrical 
stimulation of the neuron. Subsequent diffusion of the transmitter 
and interaction with the postsynaptic membrane effects communication 
or transmission of information. This transmission process, for
catecholamines, is predominately inactivated by reuptake of the dis­
charged amine into the presynaptic nerve cell. However, MAO provides 
ultimate inactivation of individual transmitter molecules by converting 
them to their corresponding carboxylic acids or alcohols. Virtually 
all the transmitter molecules which are intracellular, but extravesicular, 
are directly accessible to metabolism by MAO. And, the products of 
MAO conversion are incapable of eliciting a postsynaptic response.
III. ANALYSIS OF MAO
Most of the published assays for MAO use purified mitochondrial 
preparations as the enzymatic source. Isotonic solutions, commonly 
containing 0.25 M sucrose in a weak phosphate buffer, are utilized when 
preparing the various mitochondrial fractions. No apparent reason was 
given for the majority of the assays as to why these rather laborious sample 
preparations were performed. Regardless of the sample preparation.
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however, all reported MAO assays are conducted in hypotonic buffers, 
normally 0.050 M phosphate, in an effort to maximize the accessibility 
to MAO for substrates and cofactors by rupturing the subcellular 
components.
Analytical evaluation of the various reactants or products 
from the vitro incubation of MAO has employed the following
techniques: radiometry,^^ » 14,31 gpgg(.].Qphotometry,^^'^^'^^'^^ fluoro-
9 13 19 15 36 57 11
metry, ’ ’ potentiometry, ’ polarography, gas chromatography,
and manometry.These techniques are employed to measure one of the
10
following: (1 ) disappearance of the substrate, (2 ) consumption of
o x y g e n , (3) production of peroxide,C4) production of ammonia,
11 25
(5) formation of the aldehyde, ’ or (6 ) formation of a carboxylic
acid following enzymatic conversion of the initial aldehyde product.
9,19
Many of these techniques have inherent drawbacks. Manometric 
and polarographic techniques,which measure oxygen uptake, lack 
sufficient detection limits and selectivity. Colorimetric assays 
commonly employ substrates which are not physiological in nature, 
e.g., kynuramine(I) or p-dimethylaminebenzylamine(II):
Kynuramine
(I)
CHg CHg
p-Dimethylamine- 
benzylamine 
(II)
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A gas chromatographic assay^^ with electron capture detection also 
suffers from this drawback by using m-iodobenzylamine(III). Potentio- 
metric assays, which measure the generated ammonia or peroxide, are 
relatively rapid and exhibit moderate detection limits. However, they 
lack selectivity and are useless for studies involving mixtures of 
substrates.
An improved colorimetric procedure has been described. It is
based on a peroxidase-catalyzed reaction with a colorless fluoroscein
dye. However, the biologically important catecholamines, dopamine
and norepinephrine, cannot be used as they interfere with the oxidative
conversion of the dye into the chromophore.
The measurement of generated peroxide in MAO reactions has 
13also employed a fluorometer. The procedure is based on the reaction
of peroxide with homovanillic acid (HVA). In the presence of peroxidase,
these two species combine to form a highly fluorescent compound. This
assay also suffers from interference by catecholamines and serotonin,
since these amines block formation of the fluorophore. Fluorometric
techniques are additionally subject to error due to potential variation
of background levels of endogeneous, fluorescent materials.
Gas chromatographic and radiometric procedures have been
developed which measure aldehyde f o r m a t i o n . * 14,31 q^ e^se assays
require an extraction of the aldehyde prior to quantitation. Not only
are extractions time consuming and tedious, but studies using these
procedures have shown incomplete recovery of indole-3-acetaldehyde and
12 59
indole-3-acetic acid from solutions containing tissue residues. ’
The investigators attribute the low recoveries to nonspecific binding
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59of the radioactive metabolites to denatured protein. Based on studies 
in our laboratory, we also concur with this explanation.^
Additional difficulties can be encountered in measuring only 
the generated aldehyde. First, conversion of the aldehyde metabolite 
to its corresponding acid must be prevented. Secondly, aldehydes have 
been shown to be highly reactive; the carbonyl group of the aldehyde 
readily reacts with the free amino groups in proteins and other com­
pounds to form a Schiff's b a s e . I n  order to circumvent these dif­
ficulties, subsequent procedures have attempted to reduce the time spent 
by the aldehydes in the incubation mixture. Alternatively, total con­
version of the amines into their corresponding carboxylic acids by
the addition of aldehyde dehydrogenase (AD) may be employed, followed
9 19 20
by quantitation of the acids. ’ ’
AD, like MAO, is also found in brain mitochondria. Early
information leading to the discovery of AD in brain tissue included:
1 ) the presence of only small amounts of aldehydes in the brain as 
18products of MAO and 2) the facile production of acids from aldehydes 
by isolated brain tissues.These two pieces of data implicated an 
enzyme that readily oxidized aldehydes into their corresponding acids.
For a coupled MAO-AD assay to be quantitative, two stringent 
requirements must be satisfied. Since the AD-formed carboxylic acid is to 
be measured, it is imperative that the MAO-formed aldehyde be converted 
both immediately and stoichiometrically. In other words, the pro­
duction of the aldehyde by MAO must be the rate limiting step in the 
overall scheme. This also implies that sufficient AD be present 
to instantaneously transform the intermediate aldehyde into the acid.
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Previous work with and MAO^^ indicates that an MAO-AD
coupled reaction is a completely reasonable approach to measuring MAO 
activity. Michaelis constants and maximal velocities were reported in 
these investigations for dopamine, serotonin, and their corresponding 
aldehydes. The data is summarized in Table 3-2, where it is easily 
seen that AD exhibits much higher velocities and requires substantially 
less substrate to achieve saturation kinetics.
Based on these reports and the preceding information, an 
attempt was made to establish a procedure for the routine analysis of 
MAO using a combined MAO-AD system and quantitation by LCEC. The fol­
lowing chapter describes the results of this work which was completed 
during the winter of 1980 and the spring of 1981.
Table 3-2. Kinetic Constants for Pertinent MAO and AD Substrates^
Substrate Enzyme V
(micromolesfmin/mg protein)
5-hydroxytryptamine
(5-HT)
MAO 0.0047
5-hydroxyindoleacetaldehyde AD 84
dopamine (DA) MAO 0.0065
3,4-dihydroxyphenylacetaldehyde AD 156
^ata from references 28 (AD) and 36 (MAO).
CHAPTER 4
THE DETERMINATION OF MONOAMINE OXIDASE ACTIVITY IN BRAIN TISSUES
I. INTRODUCTION
In developing a procedure for monoamine oxidase (MAO), we 
attempted to devise a method which would be; 1 ) simple to perform and 
involve minimal sample manipulation, 2 ) inexpensive, requiring a limited 
amount of equipment and reagents, 3) rapid and capable of incorporating 
a large number of samples at one time, 4) capable of employing substrates 
which are biologically important, 5) capable of analyzing mixtures of 
substrates, 6 ) sensitive with reasonably low limits of detection, and 
7) stoichiometrically correct, or produce exactly one mole of product 
for each mole of substrate consumed. By utilizing LCEC many of these 
requirements were inherently satisfied. The liquid chromatograph easily 
and quickly separates and quantitates a relatively large number of 
substrates and products, allowing the employment of multiple substrates. 
The LCEC system is relatively inexpensive, and has previously exhibited 
low limits of detection. Additionally, the instrumentation existing 
in our laboratory at the time could be used without any major modifica­
tions. Therefore, the primary challenge was to develop a stoichio­
metrically correct procedure that was simple, rapid, and involved a 
minimal amount of sample manipulation. Optimization of the various
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parameters would also ensure the maximum sensitivity, or tissue/ 
blank ratio, for the assay.
II. DEVELOPMENT OF THE PROCEDURE
The analysis of MAO in brain tissue may be viewed as a three 
step process. Step one involves preincubation of the enzyme with 
appropriate cofactors, aldehyde dehydrogenase (AD), and other essential 
species under a specific set of conditions. The second step involves 
addition of substrate to the mixture with subsequent incubation. During 
incubation, MAO and AD transform the amine substrate into a carboxylic 
acid. Finally, the enzymatic reaction is terminated and the product 
quantitated by LCEC.
The development of this assay began with an examination of the 
chromatographic conditions for separating the electrochemically active 
components in the incubation mixture. Once an adequate separation 
was achieved, we proceeded to optimize the preincubation, incubation, 
and related parameters utilized in the assay.
The following report begins with a description of the materials 
used and a short outline of the procedure. This is followed by the 
optimization of individual parameters and an application of the pro­
cedure to the determination of MAO activity in brain parts. The con­
cluding remarks cover areas which may prove fruitful for future inves­
tigations.
III. EQUIPMENT AND REAGENTS
A. Apparatus.
1. Liquid Chromatograph, The liquid chromatograph with an
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electrochemical detector (LCEC) has been previously described by a
number of investigators (1-3; also see Chap. 1). The system used in
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the current investigation was identical to that described by Hsi 
in many aspects. It contained the following components.
2. Pump. Solvent delivery was accomplished with a Milton 
Roy Minipump, model no. 13906-1. This unit has a maximum pressure 
capability of 5000 p.s.i. and a maximum flow rate of 160 ml/hr.
3. Damping Coil. A Li-Chroma-Damp II from Handy & Harmon 
Tube Company, Norristown, PA, was employed to minimize the pressure 
fluctuations arising from the reciprocating pump. It was rated at 
a maximum operating pressure of 3000 p.s.i. The empirical lifetime 
of this unit was only ca. 2 months during continuous operation. The 
dampener failed to perform adequately due to excessive formation of 
small pinhole leaks in the collapsed portion of the coil. Consequently, 
the dampener was discarded and replaced with a comparable device from 
Waters Associates (Low Pressure Filter Assembly, part number 98060).
The Waters unit provided completely acceptable noise reduction for
this assay with a considerably longer lifetime.
4. Connecting Tubing. Stainless steel tubing (1/16" o.d. x
0.030" i.d.) was used to connect the various parts of the chromatograph.
Connectors were 1/16" stainless steel Swagelok fittings.
5. Detector. The carbon paste working electrode as well as
the reference and counter electrodes have been described in Chapter 1.
6 . Injector. Initially, a Rheodyne Model no. 7120 Sample
Injector fitted with a 20 microliter fixed volume loop was used. Later
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a Waters WISP, model no. 710A, Intelligent Sample Processor was used 
to automate the injection process.
7. Electronics. The combined potential controller and current
4
monitoring instrument was identical to that previously described.
8 . Column. The column was a 4.6 x 150 mm Ultrasphere ODS 
packed with 5 micron reverse phase particles and obtained from Beckman, 
Berkley, CA (part no. 256-06). Essential precautions required for 
proper maintenance of the chromatographic column are described in 
Appendix A2.
9. Pressure Limiter. A pressure gauge (3000 p.s.i. max.)
was electronically modified by P. Lin to limit the operating pressure
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of the entire system. It automatically shut off the pump when a predeter­
mined value of pressure, typically 3000 p.s.i., was reached or surpassed.
10. Tissue Homogenizer. For sonicated samples, a Bonifier 
Cell Disrupter, model W200P from Heat Systems Ultrasonics, Inc.,
Plainfield, NY, was used. The sonicator was fitted with a 3 mm probe.
For ground glass samples, a Fisher Dynamix stirrer (Model 43, Fisher 
Scientific, Dallas, TX) was fitted with a ground glass tissue grinder 
(part no. K-885450-0023, size C) from Kontes Glass Co., Vineland, NJ.
11. Incubator. A Sherer Controlled Environmental Chamber, 
model CEL 37-14, was used directly as an air incubator.
12. Shaker. An Eberbach model 6010 shaker, operated at 4 
cycles per second (high setting), was placed in the incubator for 
utilization.
13. Centrifuge. A Sorvall RC2-B refrigerated centrifuge, 
fitted with an SM-24 rotor, was used for all centrifugal operations.
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14. Strip Chart Recorder. An Omniscribe recorder, obtained 
from Houston Instruments, Austin, TX, was used to record all chromato­
grams. The recorder was typically operated at a setting corresponding 
to 2 0  namp of detector current for a full scale deflection.
B. Animals.
Adult male and female mice were bred in-house from the Sprague- 
Dawley ARS HA/ICR albino strain. These were maintained on a 12 hour 
light/ 1 2  hour dark cycle and allowed access to food and water ^  libitum. 
They were sacrificed by cervical dislocation, usually between the hours 
of 9 and 11 a.m. They were typically 2-3 months old, corresponding 
to body weights of 25-30 g, at the time of death.
C. Chromatographic Conditions.
1. Detector. The detector was packed with carbon paste (CP-W) 
from Bioanalytical Systems, West Lafayette, IN. The electrode was 
operated at a potential of +0.70 volts vs. a saturated calomel electrode 
(SCE). The SCE was similar in construction to that described in 
Meites.^ It contacted the chromatographic stream through a short 
piece of 3 mm Vycor rod which was held onto its tip by a piece of 
teflon tubing.
2. Mobile Phase. A buffer solution was prepared by dissolving 
29.41 grams of trisodium citrate dihydrate (0.050 M) and 21.01 grams of 
citric acid monohydrate (0.050 M) in 2.0 liters of water. The pH
of this buffer was brought to 4.3 by dropwise addition of 1 M NaOH.
Prior to use, the solution was passed through a 0.45 micron Millipore 
filter to remove particulate matter.
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3. System Operating Conditions. The flow rate was typically 
1.3 ml/min. This corresponded to a pump setting of 50.0 and resulted 
in an operating pressure of 2500 p.s.i. To minimize solvent preparation, 
the eluent from the detector was returned to the solvent reservoir to be 
recycled through the chromatographic system. The recycling of the mobile 
phase presented no apparent problems even after 1  month of continued use.
To prevent dust and other impurities from entering the system, the re­
servoir was tightly capped with a one hole stopper. The inlet and outlet 
lines passed through the single hole. The inlet line was also fitted 
with a metal-sintered filter (50 p) to prevent large particles from 
entering the pump.
D. Reagent Sources.
The following chemicals were obtained from the sources noted 
in the highest available purity.
From Sigma Chemical Co., St. Louis, MO:
6 -nicotinamide adenine dinucleotide (NAD^)
3.4-dihydroxybenzoic acid (protocatechuic acid, DB)
From Aldrich Chemical Co., Milwaukee, WI:
5-hydroxyindole-3-acetic acid C5-HIAA)
3.4-dihydroxyphenylacetic acid CDOPAC) 
dopamine hydrochloride (.DA)
5-hydroxytryptamine(serotonin)creatine sulfate monohydrate (5-HT) 
pargyline (N-methyl-N-propargylbenzylamine hydrochloride) 
citric acid, trisodium salt (sodium citrate dihydrate)
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From Mallinkrodt, Paris, KY:
citric acid monohydrate 
From Pfaltz & Bauer, Flushing, NY:
2-mercaptoethanol (EtSH)
From in-house synthesis :
5-hydroxyindole-3-carboxylic acid (5-HICA). (Synthesis 
described in Appendix Al).
All other chemicals were purchased in the highest possible purity from 
readily available commercial sources.
E. Solutions.
1. Stock Solutions. These solutions were prepared on the 
morning of analysis (See Table 4-1). The solutions were considered 
unstable and were discarded immediately after use. The values for
NAD**", 5-HT, and DA shown in the table are the derived optimum values
(vide infra).
2. 2-Mercaptoethanol. This solution was prepared by dis­
solving 100 pi or 350 pi of the mercaptan in 10.00 mis of distilled
water. Different solutions were required for each of the two substrates
investigated. The final stock concentrations were 0.143 M and 0.499 M 
for DA and 5-HT, respectively.
3. Phosphate Buffer. A 0.50 M solution of phosphate having 
a pH of 9.6 was prepared in the following manner. A 0.50 M solution 
of NagHPO^ was made by dissolving 35.5 grams of the anhydrous compound 
in 500 mis of water. A second solution, containing 0.50 M Na^HPO^, 
was made by dissolving 95.0 grams of the dodecahydrate salt in 500 mis 
of water. The first solution was then titrated with the second until
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Table 4-1. Preparation of the Stock Standard Solutions
Compound Weight of Compound
(mg)
Final
Volume
(ml)
Final 
Concentration 
(moles/I)
nad'*’ 65.20 5.00 2 .0 x1 0 “^
Internal
Standard
Stock
Solutions
5-HICA^
DSb
1.18
1 . 2 0
5.00
1 0 . 0 0
1.33x10’'^
7.79x10"^
Working
Standard
Stock
Solutions
5-HIAA^
DOPACb
1.14
.94
1 0 . 0 0
1 0 . 0 0
5.96x10"'^
5.59x10/^
Substrate
Stock
Standard
Solutions
5-HT^
DA^
34.47
1 0 . 2
5.00
5.00
1.70x10"^ 
1.08x10"
^sed when 5-HT is substrate. 
^Used when DA is substrate.
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a pH of 9.6 was obtained.
4. Homogenization Solution. A 0.050 M hypotonic phosphate 
buffer having a pH of 10.0 was prepared by first diluting each of the 
0.50 M phosphate buffers described above by a factor of 10. The solution 
containing Na^PO^ was then titrated with the solution containing NagHPO^ 
until a pH of 10.0 was reached.
5. Isotonic Sucrose. An isotonic solution of sucrose was 
prepared by dissolving 58.2 grams of this compound in 500 ml of water.
The final concentration was 0.35 M.
6 . Postincubation Solution. The solution added to the in­
cubation mixture immediately after incubation contained acetic acid 
and NaClO^. It is described as the 'homogenization solution' in 
Chapter 2.
7. Kidney Homogenate. Kidneys were removed from female 
laboratory mice and weighed in a ground glass tissue grinder. An appro­
priate volume of isotonic sucrose was added to produce a solution con­
taining 0.10 grams tissue/ml. The mixture was homogenized at a setting 
of 4 using multiple up/down strokes, transferred to a 15 ml polypropylene 
centrifuge tube and centrifuged at 4®C and 39,900 x g (18,000 rpm)
for 20 min to remove unwanted particles. The supernate was stored on 
crushed ice for use in the analysis.
8 . Brain Homogenate. To each whole brain, 4.00 ml of homo­
genization solution was added, and the mixture was homogenized on 
crushed ice by sonication (power setting 5 ; 50% duty cycle). For 
brain parts, only 1.00 mis of homogenization solution was added. This 
volume had to be adjusted to 2.00 mis for cortex samples. A 500 pi
108
aliquot of the homogenate, whether from whole brain or parts, was then 
used directly in the analysis of each sample.
IV. THE STANDARD MAO PROCEDURE
A brief diagrammatic outline of the MAO procedure is presented 
in Fig. 4-1. The brains were rapidly removed after sacrifice, placed 
in 15 ml centrifuge tubes, weighed and stored on crushed ice. Whole 
brains were used directly or dissected into seven regions (cerebellum, 
medulla-pons, midbrain, diencephalon, hippocampus, striatum, and cortex)
g
by the method of Wassil.
Kidneys were dissected by first removing the skin from the 
back of the animal. A small incision was made on each side of the 
exposed backbone, approximately one inch below the neck. The kidneys, 
easily seen as small, brownish-red bean shaped objects, were removed 
with the aid of a scalpel. These were homogenized as described above. 
During the twenty minutes required for centrifugation of the kidney 
homogenate, power was applied to the temperature controlling unit of 
the incubator, stock solutions were prepared, the centrifuge tubes 
to be used for incubation were numbered, and the reagents were 
dispensed into the labeled tubes. The volume of each reagent as well 
as the order in which it was added are presented in Table 4-2. The 
brain tissues were homogenized immediately before addition in this 
sequence. For all experiments, the total incubation volume was kept at 
1.750 mis.
After solutions 1 through 10 (Table 4-2) were added and mixed, 
the tubes were capped and the samples preincubated at 44"C, without
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in vitro MONOAMINE OXIDASE
FLOW CHART
Homogenization mixture Sacrifice
phosphate buffer, pH=9.6 Weigh Brain
Homoqeni ze
Preincubation Mixture sonication
EtSH/PO^'^/NAD'^/HjO , 
Internal Standard, 
Kidney homogenate Preincubate
20 min. @ 44°C
Inactivate Enzyme 
C10~/H0Ac
Jg
Incubate Add 5-HT
4--
20 min @44°C
or DA
Centri fuge 
27,000 X g, 30 min
Supernate ^ Quantitate
LCEC
Figure 4-1. Flow Chart for Monoamine Oxidase Procedure.
Table 4-2. Reagent Volumes of Stock Solutions Used in MAO Assay
Reagent and 
Order of Addition
Quantity
(microliters)
Final Concentration 
in Tissue Samples 
(M)
Final Concentration 
in Standard Samples 
(M)
Final Concentration 
in Blank Samples 
(M)
1. Phosphate buffer 500 0.14 0.14 0.14
2. Homogenization 500 —  — 0.014® 0.014®
solution
3. 0.34 M Sucrose 250 - 0.048 -
4. NAD"^ 1 0 0 0.00113 0.00113 0.00113
5. Water 1 0 0 added® - added®
5-HT as Substrate
6 . EtSH 1 0 0 0.0330 0.0330 0.0330
7. 5-HICA 1 0 0 7.6 x1 0 "^ 7.61x10“^ 7.61x10“^
8 . 5-HIAA 1 0 0 — — 3.19x10“^
11. 5-HT 1 0 0 9.67x10“^ 9.67x10"^ 9.67x10“^
DÂ as Substrate
6 . EtSH 1 0 0 0.00813 0.00813 0.00813
7. DB 1 0 0 4.42x10"^ 4.42x10“^ 4.42x10“^
8 . DOPAC 1 0 0 — — 3.19x10“^ — w
1 1 . DA*^ 1 0 0 6.16x10“^ 6.17x10“^ 6.17x10“^
9. Kidney homogenate 250 36 mg/ml — 36 mg/ml
10. Brain homogenate® 500 36 mg/ml — -
Total Volume 1750
MO
^substitutes for brain homogenate ^substitutes for kidney homogenate ^substitutes for 1 0 0  microliters 
of working standard *^added after 20 min preincubation ^assuming an ave. brain wt. of 0.5 gm
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shaking, for 20 minutes. After preincubation, the substrate (either 
5-HT or DA) was added, a stopwatch started, and the samples incubated 
for a further 20 minutes. During incubation, the samples were con­
tinuously subjected to shaking at 4 cycles/sec with the tubes in a hori­
zontal position having the long axis of the tubes parallel to the dir­
ection of shaking. The measured pH of the incubation mixture was 8.1. 
After 19.0 minutes of incubation, the tubes were removed from the incu­
bator. The reaction was terminated at 20.0 minutes by placing a 250 pi 
aliquot of the reaction mixture into 750 pi of the postincubation solu­
tion. The tubes were capped, mixed, and centrifuged for 1 hr. at 39,900 
X g (18,000 rpm) and 4°C. The supernatant fractions were decanted into 
clean, labeled 1.5 ml polypropylene centrifuge tubes and stored on 
dry ice until analysis by LCEC. Between 5 and 20 pi of supernate were 
typically required for separation and quantitation of the reaction 
product(s).
V. CALCULATIONS
Calculations were virtually identical to those described 
by Wong.^  The amount of acid formed by the deamination and dehydro­
genation of the amines is a direct measurement of the MAO activity.
The results, expressed as nanomoles product/milligram wet tissue/ 
minute (nmol/mg/min) were calculated as follows: 
activity(nmol/mg/min) =
.^ sample \lank.(nmol acid in working std.)______________
(milligrams tissue)(incubation time, min)
where
/peak height, acid______
peak height, int. std.)
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The and values represent the average ratios for all
standard samples and Blank samples, respectively. The acid refers
to 5-HIAA or DOPAC and the internal standard refers to 5-HICA or DB;
the choice as to which is appropriate depends on whether 5-HT or DA,
respectively, is used as the substrate. The weight of tissue added to
each incubation tube was calculated as follows:
wt. tissue incubated (mg) =
(mis tissue homogenate taken)(wt. tissue, g)__________
(mis homog. solution taken + Cwt. tissue, g)/(1.2 g/ml))
This assumes a density of 1.2 g/ml for the brain tissue.
Unless otherwise specified, each result represents the average
of at least three separate determinations. All uncertainties are ex­
pressed as the standard deviation (S.D.). Statistical significance was 
examined by use of Student's t-test.^
VI. INVESTIGATION OF CHROÎ-ÎATOGRAPHIC CONDITIONS
Utilizing the chromatographic principles and theories pre­
sented in Chapter 1, a separation was achieved for MAO determinations 
which provided adequate resolution between neighboring chromatographic 
peaks. The total time requires was less than 12 minutes for a single 
chromatogram. The conditions employed also permit the simultaneous 
quantitation of 5-HIAA and DOPAC as well as their associated substrates 
and internal standards. A sample chromatogram, shown in Fig. 4-2, 
illustrates the separation achieved for 5-HIAA, DOPAC, 5-HT, and DA.
The related chromatographic data is presented in Table 4-3, while the
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inj ect
10
minutes
Figure 4-2, Typical Chromatogram from an MAO Analysis Employing Both 
Dopamine and Serotonin as Substrates. Numbers used for peak identification 
are defined in Table 4-3.
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Table 4-3. Chromatographic Data for Compounds Associated with MAO 
Determinations
Compound
Retention Time 
(min:sec)
Capacity Factor 
(k*)No. Identification
0 Solvent --- 0.52
1 NADH 0:51 1.23
2 Unknown 1:36 2 . 1 0
3 Dopamine (DA) 2  : 2 2 2.57
4 3,4-Dihydroxybenzoic 
Acid (DB)
3:29 3.56
5 3,4-Dihydroxyphenyl- 
acetic Acid (DOPAC)
4:36 4.55
6 Unknown 5:04 5.32
7 Serotonin (5-HT) 6:51 6.53
8 Impurity from 5-HIAA 7:58 7.52
9 5-Hydroxyindole-3- 
acetic acid (5-HIAA)
9:09 9.15
1 0 5-Hydroxyindole-3- 10:38 
carboxylic Acid (5-HICA)
10.26
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eluting solvent is described in Section III.C.2 (vide supra).
These same chromatographic conditions are also suitable for the analysis 
of other electrochemically active substrates. For example, 3-MT (k'=
6.5) can be studied through its product HVA (k’=10.0) either alone or in 
combination with DA and/or 5-HT. Due to their extremely small capacity 
factors, the 6 -hydroxylated catechols, NE and NOBMET, cannot be deter­
mined using these conditions. A solvent having a low pH (less than 4), 
some sample clean-up, and the use of quaternary ammonium salts as ion- 
interaction agents are suggested as possible modifications to make 
these species accessible to the interested reader.
Optimization of the applied potential for the electrochemical 
detector focused on providing the maximum sensitivity with a minimum 
amount of baseline noise. For quantitative work, it is also preferred 
to have a signal which is relatively independent of the applied working 
potential. This is helpful in avoiding major signal fluctuations as a 
result of inevitable, but minor, fluctuations in applied potential.
To minimize this problem, the potential of the working electrode was 
successively varied while a constant amount of the investigated compounds 
were injected into the chromatograph. The observed peak heights at 
each potential were recorded. The results are shown in Fig. 4-3 for 
5-HIAA and 5-HICA. The ratio of the peak heights is also presented 
in this figure. The background current or noise, although not shown, 
increases in a fairly linear fashion over the range shown. For maximum 
sensitivity with minimum noise, a potential was selected on the portion 
of the graph where the peak height ratio is relatively independent 
of the applied potential, i.e., +0.700V vs. SCE. This value was used
1.01.0
^ 7
.50
o>
_ L _
.62
_ X _
.67
_1_
.77.57.52 .72.47 .82.37 .42
*TJn>
QX-
X
2.
(5
3-
Applied Voltage( volts vs. SCE)
Figure 4-3. Effect of Applied Working Potential on the Peak Height Ratio of 5-HIAA to 5-HICA. 
Symbols: peak height ratio (o); peak height 5-HICA (+); peak height 5-HIAA (*).
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in all subsequent work. Similar studies of DOPAC and DB were not 
undertaken. These compounds had been previously shown to be easier 
to oxidize than the indolic species by cyclic voltammetry; thus, the 
value of +0.7G0V is also completely applicable to their quantitation.
The linearity of the peak height ratio [(peak height of acid)/ 
(peak height of internal standard)] as a function of the amount of acid 
was also studied for both DOPAC and 5-HIAA. The results are plotted 
in Fig. 4-4. The concentrations were derived from stock standard 
solutions by appropriate dilution. No tissue was present in this study. 
As can be seen, excellent linearity was obtained for a range of values 
which encompasses those typically encountered for 5-HIAA and DOPAC 
in an MAO assay.
VII. OPTIMIZATION OF INCUBATION CONDITIONS
9
The conditions used by Lovenberg et al. were initially 
employed for the MAO assay without any major modifications. However, 
the currently developed method is unique in a number of respects.
Thus, we decided to carefully examine some of the more important 
parameters. An appropriate range for each parameter was initially 
selected and examined in a rather cursory manner to determine a value 
which produced an optimum activity. The values derived in this manner 
were then combined to form a 'tentative' optimal procedure. These 
values also were used to indicate appropriate ranges to be further 
investigated. Using the tentative procedure and the new ranges, each 
parameter was reexamined in detail in the order presented below. The 
optimized value for a given individual parameter was always incorporated
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Figure 4-4. Relationship of the Peak Height Ratios DOPAC/DBA (o) and 5-HIAA/5-HICA (*) as a 
Function of the Amount (nmol) of Injected DOPAC and 5-HIAA, Respectively.
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into the tentative procedure immediately after it was determined. Both 
the initially employed conditions and the ones used in the beginning 
tentative procedure are presented in Table 4-4.
A. Incubation Temperature
A review of previous procedures for MAO showed no single 
incubation temperature common to all. Room temperature,^^ 30®C ’
and had all been employed. The consensus appeared to be
Table 4-4. Procedural Conditions Used At Various Stages in the 
Development of the MAO Assay.^
Condition Initial Procedure^ Intermediate, 
'Tentative' Procedure
Temperature 37®C 37"C
Kidney Homogenate 0 36 mg/ml
2-Mercaptoethanol 0 33.0 mM (5-HT) 
8.3 mM (DA)
pH 7.4 8 . 1
Nicotinamide 1 mM 0
nad'*’ 1 mM 1
Substrate
Concentration
1.18 mM (5-HT) 
not tested (DA)
1.18 mM (5-HT) 
0.50 mM (DA)
Incubation Time 30 min 2 0  mip
Preincubation Time 1 0  min 2 0  min
Homogenization Ground Glass' Ground Glass
All concentrations are referred to the final incubation mixture.
^Patterned after Lovenberg et al.^
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at 37°C, although none of the papers reported optimization of this 
parameter.
Initially, temperatures of 30, 37 and 44®C, were investigated 
with 37®C yielding the maximum activity. However, once the tentative 
procedure had been established, the maximum activity was observed to 
occur at 44®C. The results are presented in Table 4-5. Preincubation 
was performed at the same temperature as incubations to eliminate time 
delays that would have been required for stabilizing the air bath.
B. Aldehyde Dehydrogenase.
The conversion of amines into the corresponding acids by MAO 
relies on a second, NAD"*" dependent enzyme : aldehyde dehydrogenase
(AD). Kinetic measurements of MAO determined by the amount of acid 
formed are reliable only if the MAO activity is rate limiting. The 
AD must spontaneously convert the aldehyde(.s) produced by MAO into 
the corresponding acid(.s).
The need to fortify the brain tissue homogenates with AD 
originated with the commencement of this work. Incubated tissue 
samples initially exhibited a broad peak eluting near 5-HIAA when using 
5-HT as the substrate (Fig. 4-5). This peak was partially eliminated with 
the addition of 2-mercaptoethanol (EtSH), a compound known to stimulate 
AD; simultaneously, an increase was observed in the measured 5-HIAA 
activity. This led us to believe that the broad, unidentified peak 
was 5-hydroxyindole-3-acetaldehyde. Additional evidence to support 
this hypothesis was provided when two broad peaks appeared following 
incubation with both 5-HT and DA in the absence of NAD"*", a cofactor 
for AD (Fig. 4-6A). These peaks disappeared when NAD"*" was incorporated
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m i n u t e s
Figure 4-5. Removal of Broad Peak by the Addition of EtSH. Fig. A was 
obtained with no EtSH. Fig. B was obtained with an EtSH concentration 
of 0.033 M. Both mixtures contained mouse kidney and NAD"^ . (For chromato­
graphic conditions see section III-C). Peaks are; solvent (1), 5-HT (2), 
5-HIAA (3), and 5-HICA (5).
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Figure 4-6. Addition of NAD to Incubation Mixtures. Fig. A was obtained 
with no NAD^; Fig. B was obtained with NAD"''. Note the absence of the two 
broad peaks in chromatogram B. (Chromatographic conditions are the same 
as in section III-C except the pH was 4.6 and 0.080 nM sodium octyl sulfate 
was added to the mobile phase.) Peaks are: solvent (1), 2,3-dihydroxybenzoic 
acid (2), DOPAC (3), DA (4), 5-HT (5), 5-HIAA (6 ), 5-HICA (7).
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Table 4-5. MAO Activity vs. Incubation Temperature for Whole Mouse 
Brain
Incubation
Temperature
(°C)
Activity DA 
(nmols DOPAC/mg/min)
Activity 5-HT 
(nmols 5-HIAA/mg/min)
30 0.05621.0021 0.04181.0057
37 0.08831.0052 0.06061.0055
44 0.1111.0040 0.07971.0072
50 0.1031.0110 0.06531.0046
into the reaction mixture containing added AD (Fig. 4-6B).
The capability to detect these aldehydes in MAO incubation
mixtures gives the LCEC assay definite advantages over other MAO-AD
coupled procedures. Other assays commonly involve coextraction of the
9
acids and aldehydes into a nonaqueous solvent. Such extractions do 
not, however, provide any distinction between aldehyde and acid. This 
causes difficulties in distinguishing between MAO and AD effects. The 
LCEC assay partially alleviates this problem by allowing any substantial 
amount of aldehyde to be easily seen in the chromatogram.
It was considered justifiable to add a source of AD to prevent 
the possibility of this enzyme being a limiting factor in the overall 
reaction. A commercial preparation of AD was first attempted. One 
milligram of this preparation reportedly will oxidize 4.5 pmol of 
acetaldehyde to acetic acid in one minute at pH = 8.0 and 25"C. This
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AD was added to the incubation mixture in amounts ranging from 0 to 1.1 
mg. Surprisingly, the highest activity occurred when no commercial AD 
was added at all! This approach was thus abandoned. But, previous 
investigators had reported enhancement of MAO assays by incorporating 
additional AD.^*^^ Studies with guinea pigs, e.g., 
had shown that MAO activity increased when kidney was used as a source 
for AD. In the light of this information, isotonic kidney homogenates 
were prepared and added to the incubation mixtures. The kidney homo­
genates did, indeed, produce higher activities (Fig. 4-7). A homo­
genate containing 50 mg of tissue was subsequently added to all samples.
During the course of this optimization work, notable sex dif­
ferences were observed. Initially, the mice used were exclusively 
females. However, as our female population slowly diminished, a switch 
was made to males. A considerable drop in observed MAO activity was
noticed at this time, coupled with the reappearance of the aldehyde
peak in the chromatography. An examination of the literature revealed 
that a sex difference in kidney AD had previously been reported for rats^^ 
where the velocity for females was over twice that of males. In light 
of our findings and these reports, only female kidney preparations were 
used for succeeding investigations.
The possible necessity for blanks was also considered at this
point in the initial optimization. Blanks would be required if either
the endogenous amount of product(s) in brain homogenates or the amount 
of product(s) produced by incubation without brain tissues were considerable. 
A substantial amount of endogenous compound was eliminated due 
to the relatively low concentration of such species found in the
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Figure 4-7. Effect of Female Mouse Kidney Homogenate on MAO Activity. Substrates: 5-HT (.*), and
DA (o). Amount of kidney homogenate Indicated were added to each Incubation mixture.
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brain. For example, a typical whole brain contains 400 ng 5-HIAA/gram 
wet tissue. A typical MAO assay, employing 63 mg tissue and incubated for 
20 min, yields an average activity of 0.0835 nmol/mg/min. Calculating 
the 5-HIAA produced by the enzyme and that derived from the endogenous 
content, we find:
endogenous: 0.33 nmol 5-HIAA
MAO produced: 105.0 nmol 5-HIAA
Thus, under the given conditions, the amount of product generated by the 
enzyme is 300 times greater than that commonly encountered in brain tissues. 
However, when incubations were performed without any brain homogenate, 
a substantial amount of product was formed. Representing approximately 
5-10% of the usual activity, this material was presumed to result from 
residual MAO activity in kidney homogenates. This observation simply 
means that blanks are required and must be included for assays employing 
this procedure.
C. Interference by Aldehyde Reductase.
The possible interference by aldehyde reductase, which would
convert the intermediate aldehyde into an alcohol, was considered but
eliminated for a number of reasons. First, NADH, the primary cofactor
for aldehyde reductase, is only present in very low concentration in
the incubation mixture. Secondly, aldehyde reductase is notably in-
37hibited at alkaline pH values. Finally, there are only low concen-
37trations of this enzyme in brain tissues.
D. 2-Mercaptoethanol (EtSH).
The addition of EtSH to the incubation mixture noticeably 
increased the activity. This compound is frequently employed in assays
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21 20 
as a general enzyme activator. Houslay et al., for example, ob­
served activation upon treatment of tissue preparations with EtSH.
22
Lundquist included it in his assay for AD. Sigma Chemical also sug­
gests addition of thiols to their purified AD preparations. These 
reports as well as our preliminary observations clearly indicated the 
inclusion of EtSH. When EtSH was added to incubation mixtures containing 
either DA or 5-HT as substrate, we obtained the results shown in Fig.
4-8. It is not currently known why the two substrates require unique 
EtSH concentrations. One possibility might be the involvement of
27
multiple forms of AD; however, isozymes of AD have not yet been reported. 
Another possibility is that the EtSH is having a differential effect 
on the two isozymes of MAO in addition to its effect on AD.
E. pH Optimization.
The control of pH was accomplished by the addition of a Q.50 M 
solution of a phosphate buffer. During optimization, the buffers were 
prepared by mixing together various amounts of 0.50 M solutions of mono-, 
di-, and tri-sodium phosphate. This molarity did not provide the desired 
buffer capacity, but higher concentrations were not practically obtainable 
due to dissolution problems. The resulting pH of the incubation mixture 
was, thus, measured as a function of the buffer pH (Table 4-6) using the stan­
dard amount of brain tissue (60 mg/sample). The resulting pH was also 
measured as a function of the amount of brain tissue (Table 4-7) using 
the standard buffer pH of 9.6. The results were not surprising, since
a simple titration of phosphoric acid with 0.10 M NaOH clearly shows
30a lack of buffering capacity in this pH range. The final pH of the 
incubation mixture was, thus, measured for each test in the optimization
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Figure 4-8. Effect of Mercaptoethanol on MAO activity. Substrates: 5-HT (*), and
DA (o).
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procedure. The resulting activities for the two different substrates 
were plotted as a function of the measured pH (Fig. 4-9). The pH 
which produced the maximum activities for both substrates fell in the 
range of 8 .0-8.4. This is in agreement with others who have measured 
MAO activities through the acid product in preparations incorporating 
AD.16’18’20 However, the majority of assays which measure MAO do not 
incorporate AD and, thus, focus on the aldehyde product. Such assays 
have reported pH optima in the range of 7.2-7.8 .^^ 14,29,23 26
The discrepancy between the optimum pH for the single enzymatic 
reaction (aldehyde measurement) as opposed to the coupled reaction 
(acid measement) may possibly be due to some unknown cooperativity 
between MAO and AD. Alternatively, the aldehyde product of the single 
enzyme assays may experience more extensive interaction with macro- 
molecular (and other) amines at elevated pH values. Such reactions 
would lead to an excessively and incorrectly low pH optimum.
The use of other buffering agents was not investigated in
the current study. The obvious alternatives would be TRIS (tris-
31hydroxymethylaminomethane) and borate. However, Tabakoff has 
already reported that TRIS causes a 30% reduction in MAO activity.
Table 4-6. pH of Incubation Mixtures as a Function of the Phosphate 
Buffer pH.
pH of Phosphate Buffer 7.51 8.42 9.57 10.16 10.51 11,24
pH of Incubation Mixture 7.51 7.98 8.23 8 . 6 8  9.36 11.09
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Figure 4-9. Effect of pH on MAO Activity. Substrates: 5-HT (*) and DA (o).
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Table 4-7. pH of Incubation Mixture as a Function of the Amount of 
Added Brain Tissue.^
Weight of Tissue (mg) 5.89 11.8 23.6 35.3 58.9
pH of Incubation Mixture 8.26 8.22 8.18 8.15 8.13
^All other components of samples were the same as those described for 
the standard MAO assay. The amount of tissue was adjusted by varying 
the concentration of the tissue homogenate as expressed in mg/ml.
13
And, Snyder has observed a decrease in MAO activity when using either
borate or TRIS.
The possible effects of ionic strength were also considered
31but not investigated. Tabakoff has previously found no difference
in MAO activity with a threefold change in ionic strength, and Houslay
20
et al. have reported virtually identical results.
F. Nicotinamide.
Some researchers have included nicotinamide in incubation
9 19
mixtures of coupled MAO assays. ’ However, no effect on MAO activity
was observed in the current investigation for nicotinamide concentrations
-7 -3
varied between 1 x 10 and 1 x 10 M. Thus, nicotinamide was eliminated 
from the procedure.
G. NAD"*".
NAD"*" was added to incubation mixtures containing either DA or 
5-HT. Plots of MAO activity as a function of the concentrations of
132
this component are shown in Fig. 4-10. While the observed activity 
is virtually constant for either substrate with concentrations above 
5.0 X 10 ^ M, a value of 1.0 x 10  ^M NAd"*" was selected as optimal to 
provide a comfortable margin of safety. This value is in strong agree­
ment with the work of Dietrich et al., who consistently used the same
17 28 32concentration in their studies with aldehyde dehydrogenase, ’ ’
-4 20and Houslay et al., who used 7.5 x 10 M in their work.
H. Substrate.
The effects of the substrate concentration in the incubation
mixture are presented in Fig. 4-11. The 1/V vs^ . 1/S plots were used to
determine the K and V values. The K results are compared to other m max m
reported values for this constant in Table 4-8. The V for 5-HTmax
and DA, respectively, were 0.0910 nmol/mg/min and 0.164 nmol/mg/min.
Since most of the previously reported values for are for purified
mitochondrial preparations and are expressed for mg protein rather than 
per mg tissue, no direct comparisons can be made at this time. Based 
on the values and the ease of preparation, optimal substrate concen­
trations of 9.67 X 10 ^ M for 5-HT and 6.17 x 10 ^ M for DA were selected.
I. Incubation Time.
The linear accumulation of product with incubation time is shown 
in Fig. 4-13. From this figure, it is apparent that the reagents des­
cribed in Table 4-2 are present in sufficient quantity to sustain a 
constant production of acid for 2 0  minutes.
J. Preincubation Time.
Preincubation of some enzymes with their cofactors has been 
shown to occasionally provide greater activities.^ The results of
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Figure 4-12. Effect of Dopamine Concentration on MAO Activity.
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Table 4-8. Comparison of K Values for DA and 5-HT as Substratesm
in MAO Analyses'
Substrate Technique MAO Source Reference
5-HT LCEC 71 mouse brain 
homogenate
this work
5-HT Radiometric 130 rabbit brain 
purified 
mitochondria
1 2
5-HT Potentiometric 80 rat brain purified 
mitochondria
15
5-HT Potentiometric 57 rat liver purified 
mitochondria
36
DA LCEC 167 mouse brain 
homogenate
this work
DA Radiometric 2 1 0 rabbit brain 
purified 
mitochondria
1 2
DA Spectrophotometric 2 1 0 rat liver purified 
mitochondria
2 0
DA Potentiometric 171 rat liver purified 
mitochondria
36
'The literature values for techniques other than LCEC refer to samples 
which are not fortified with AD.
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Figure 4-13. Effect of Incubation Time on MAO Activity. Substrates: 5-HT (') and 
DA (o).
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preincubating samples for MAO determinations are shown in Fig. 4-14.
As can be seen, activities are 20 to 50% higher after about 20 minutes 
of preincubation. It is believed that this time allows the enzyme, 
in the presence of the added substances, to assume an appropriate 
structural configuration. An increase in the solubility of the 
enzyme with increased temperature may also occur. Another possible 
advantage of preincubation is obtained by raising the temperature 
of the mixture to the optimal value prior to addition of substrate.
This helps to eliminate any non-linearity of activity with incubation 
time.
K. Sonication and Ground Glass Homogenization.
It is much more convenient, from a procedural aspect, to 
homogenize small tissue samples like brain parts with ultrasonics. The 
small tip of the sonicator fits very nicely into the constricted bottom 
of a 1.5 ml centrifuge tube. In the previous experiments, however, 
whole brains were homogenized with ground glass due to anticipated 
destruction of MAO by ultrasonication. But, to our surprise, a comparison 
of sonication versus ground glass homogenization, given in Table 4-9, 
showed activities to be significantly higher in the sonicated samples.
We feel that sonication might provide better disruption of particulate 
matter, thus increasing exposure of the mitochondrial bound MAO and, 
possibly, increasing the solubility of the enzyme. It should be noted 
that these studies employed brain homogenates derived from males instead 
of the usual female mice, although we do not believe this would have 
any effect on the outcome.
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Figure 4-14. Effect of Preincubation on MAO Activity. Substrates: 5-HT (*) and 
DA (o).
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Table 4-9. Comparison of Homogenization Methods for the Determination 
of MAO Activity
Substrate Activity (nmol/mg/min) 
Ground Glass Sonication
DA
5-HT
0.0677+.0047
0.03601.0032
0.07381.0041
0.04341.0039
L. Shaking.
The effect of shaking the reaction tubes during incubation 
was studied using DA as the substrate. The values obtained were 0.0148± 
.0007 nmol/mg/min for still samples and 0.133±.004 for samples which were 
shook. Needless to say, shaking was continued for all further 
experiments.
M. Oxygen.
Our laboratory is currently not equipped to measure oxygen con­
centrations in gas or liquid samples. Nonetheless, a simple experiment 
was conducted to test the effect of high oxygen levels on MAO activity.
A series of tubes containing male mouse brain tissue were filled with 
pure oxygen, DA was added as the substrate, the tubes were tightly 
capped, and the samples were incubated along with similar samples con­
taining an air atmosphere. The results were 0.1105+.0107 and 0.0652+
.008 nmol/mg/min for oxygen-enriched and regular samples, respectively.
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As expected, the oxygen samples provided much greater activities. A 
problem occurred, however, with the oxygen samples. After incubation 
at 44“C, the samples containing oxygen were very dark purple, indicating 
the chemical destruction of DA by oxidation. The effect of these 
degraded compounds on MAO is unknown, but it should be investigated if 
further work is to be done using oxygen sensitive compounds as substrates. 
N. Stability of Samples Prior to Injection.
After the MAO activity was halted by addition of the post­
incubation solution, the samples were centrifuged and stored on dry ice 
until immediately before injection into the LCEC system. Studies were, 
thus, conducted on both working standards and brain samples to examine 
possible sample degradation with storage. Samples were prepared using 
two different postincubation media, 1.0 M HCl and 1.0 M HOAc/0.40 M 
NaClO^. These were kept at two different temperatures, dry ice and 
room temperature, and analyzed at various times following preparation.
The results, shown in Table 4-10 for standard samples, indicate the 
instability of the 5-HIAA in 1 M HCl at room temperature.
The corresponding results for tissue-containing samples exhibited less 
sensitivity to storage. Thus, the HOAc/NaClO^ mixture was selected as 
the postincubation medium and all samples were stored on dry ice.
0. Enzyme Concentration.
The relationships between the enzyme concentration and the rate 
of acid production for the two substrates are shown in Fig. 4-15.
The enzyme concentration was varied By modifying the concentration 
of the tissue homogenate (mg/ml). The resulting range of tissue weights 
incorporated into individual samples, 5-60 mg, is appropriate for either
Table 4-10. Stability of Standard Samples in Different Media Following Storage at Various Times 
and Temperatures.
Temperature Postincubation
Medium
Compounds
Investigated
Peak Height Ratio^ 
Start 6  hrs 3 days
% change 
after 6  hrs
23°C HCl DOPAC/DB 0.57 0.56 0.56 2 %
23°C HOAc/NaClO^ DOPAC/DB 0.57 0.57 0.56 0 %
dry ice HOAc/NaClO^ DOPAC/DB 0.64 0.63 0.63 2 %
23°C HCl 5-HIAA/5-HICA 2.08 9.29 — — 347%
23°C HOAc/NaClO^ 5-HIAA/5-HICA 2.60 2.69 - 3%
dry ice HOAc/NaClO^ 5-HIAA/5-HICA 2.23 2.32 3.46 4%
to
^atio of acid to internal standard.
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Figure 4-15. Relationship Between MAO Activity and the Amount of Brain Tissue 
Added to Incubation Mixtures. Substrates: 5-HT (*) and DA (o).
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mouse brain parts or whole brain.
P. Stoichiometry of the Method
Once all the various parameters had been optimized, a stoichio­
metric analysis of the coupled MAO-AD determination was conducted. The 
relationship between the amount of substrate consumed and product formed 
is given in Table 4-11. Since the MAO activities, as calculated from 
both substrate disappearance and product formation show no statistical 
difference, the enzymatic procedure is stoichiometric. One notable 
exception for this test is that the substrate added to individual samples 
was reduced by a factor of three from the optimal value.
Q. Summary of Optimization.
The various parameters investigated during the optimization 
of the current procedure are presented in Table 4-12. The initial 
conditions, ranges examined, and final values are also presented in 
this table.
Table 4-11. Stoichiometric Relationship of Enzymatic Reaction
Substrate Compound Measured Observed Activity (nmol/mg/min)
5-HT 5-HIAA 0.0560+.0035
5-HT 0.0565±.0047
DA DOPAC 0.149±.003Q
DA 0.142+.0063
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Table 4-12. Summary of the MAO Procedure Optimization
Parameter Initial Value Range Optimal Value
Incubation 
Temperature (°C)
37 30-50 44
Kidney Homogenate 
AD (mg tissue)
none 0-55 50
Mercaptoethanol
(mM)
0 0-83 8.3 (DA), 
33.0 (5-HT)
pH 7.4 7.1-9.5 8 . 1
Nicotinamide (M) none
-7 -3
1 0  - 1 0 0
NAD’*’ (dM) none 0-54 1 . 0
Substrate 
Concentration (mM)
1.18 (5-HT) 
0.50 (DA)
0.05-0.97
0.05-0.99
0.97
0.62
Incubation 
Time (min)
30 0-30 2 0
Preincubation 
Time (min)
1 0 0-30 2 0
Homogenization Ground Glass Ground
Glass/
Ultrasonics
Ultrasonics
Shaking No Yes/No Yes
Sample Storage 
Prior to Injection
Temperature dry ice room temp./ 
dry ice
dry ice
Time (hr.) <24 0-72 <72
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VIII. APPLICATION OF FINAL PROCEDURE.
The results of typical male mouse whole brain and brain parts 
MAO determinations are given in Table 4-13. For the determination of 
MAO activity in brain parts, the samples were split into two groups. 
Cerebellum, midbrain, and medulla-pons were run the first day, while 
the diencephalon, cortex, striatum, and hippocampus were stored on dry 
ice for analysis on the second day.
The whole brain activity, as calculated by summing the con­
tribution from individual parts, was found to be 0.0895 and 0.0839 nmol/ 
mg/min for DA and 5-HT respectively. These values are comparable to 
the values obtained by assessing whole brain directly, i.e., 0.0982 
and 0.0797, respectively. Female mice subjected to the same procedure 
showed a somewhat higher whole brain activity by summing the contribution 
from individual parts: 0.119±.009 and 0.0896±.0108 nmol/mg/min for DA and 
5-HT. The blank values, or MAO activity contributed by the kidney 
homogenate, were typically 0.0078 and 0.0102 nmol/mg/min (S.D. = 0.001) 
for DA and 5-HT, respectively. Thus, the kidney preparations contribute 
ca. 10% of the total measured MAO activity. Forty to fifty samples 
could conveniently be run with the current procedure on a single day.
IX. PHARMACOLOGICAL EFFECTS
As further evidence for the general applicability of the 
developed MAO procedure, a brief pharmacological study was undertaken. 
Previous reports have clearly indicated the existence of two forms of 
MAO, A and B. These two forms can be differentially inhibited and 
have different substrate selectivities. The classification of MAO
Table 4-13. MAO Activity in Selected Regions of Male Mouse Brain Tissue
Whole Brain Cerebellum Midbrain Medulla-Pons Diencephalon Hippocampus Striatum Cortex
Tissue Weight 
(rag)
475+20 48.0+4.0 32.8+8.5 31.0±7.1 58.4+14.3 30.9±3.6 38.613.1 180110.5
Activity (DA) 
(nmol/mg/rain)
0.0982+.016 0.112+.009 0.129+.007 0.115+.016 0.0966±.016 0.0897+.009 0.09081.005 0.07071.001
Activity (5-HT)0.0797±.007 
(nmol/mg/min)
0.124±.003 0.145+.017 0.135±.100 0.0784+.020 0.07951.014 0.09671.009 0.05421.005
Activity Cal­
culated from 
Parts
DA 0.0895
5-HT 0.0839
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isozymes is based on the highly selective inhibition of each form by
33clorgyline and deprenyl. However, these compounds were not available 
at the time this study was being conducted. Instead, pargyline, a 
partially selective inhibitor of MAO-B, was added to samples to examine 
its effect on 5-HT (a type A substrate) and DA (a type A+B substrate).
The results are shown in Fig. 4-16. As expected, the results for DA 
do not exhibit the double sigmoidal curve which would have been seen 
with a highly selective inhibitor like deprenyl. However, a slightly 
increased susceptibility to lower pargyline concentrations is shown by 
DA than 5-HT.
X. CONCLUDING REMAEKS AND AREAS FOR FURTHER INVESTIGATION.
A. Areas for Further Investigation.
Comparison of MAO activities obtained with the current pro­
cedure to those obtained with other procedures proved to be fruitless.
Most of the published reports describe activities in units of nmol/min/mg 
protein from purified mitochondria preparations or plasma samples. The 
advent of modern analytical techniques with their associated low detection 
limits would appear to have removed the necessity of purified preparations.
Thus, we would suggest that the current procedure be compared to, e.g.,
35
the radiochemical procedure using the same, wet tissue or mg protein, 
basis. Similarly, the application of this assay should also be extended 
to include other tissues and biological fluids.
Three potentially significant advantages of using an LCEC assay 
for MAO determinations have yet to be fully investigated. First, the 
high resolution afforded by the chromatography provides the researcher
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Figure 4-16, Pharmacological Effect of Pargyline on the iri vitro MAO 
Activity of Whole Mouse Brain Tissue. Substrates: 5-HT (*) and DA (o)
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with the capability to simultaneously analyze the products derived from 
multiple substrates. Under the currently employed conditions, 3-MT,
5-HT, and DA can all be investigated separately or concurrently. This 
capability is not provided by any other published assay. A preliminary 
study with a mixture of 5-HT and DA showed no inhibition of the activity 
for 5-HT; however, the activity for DA was cut almost in half when 
compared to determinations using only a single substrate,
A second area which was not thoroughly investigated was the 
limit of detection for this assay or the minimum amount of tissue needed 
to perform the experiment. However, a theoretical calculation was per­
formed to derive this value. Assuming an activity of 0.090 nmol/mg/min, 
a 20 minute incubation, and a detection limit of 0.15 pmol for 5-HIAA, 
the amount of tissue required would be 0.00008 mg or 80 ng! This number 
brings to mind the possibility of determining MAO activities in single 
cells.
A third possible extension of the current procedure would make 
it capable of employing even non-electrochemically active substrates.
This generalized approach would focus on the measurement of NADH in 
the incubation mixture. NADH, the reduced form of NAD^, is produced 
from the action of AD on the MAO-produced aldehyde intermediate. 
Preliminary electrochemical studies of NADH have shown an 0.65
volts vs. SCE using a carbon paste electrode and run in solvent currently 
employed in the chromatography (Fig. 4-17). Typical chromatograms from 
an incubation mixture and a working standard containing NADH are shown 
in Fig. 4-18. These figures illustrate the potential quantitation 
of this compound. A comparison of the two chromatograms reveals that
(+» vs SCE (voltsi
1 D 050 OO -050
(+) ^ E vs SCE (volts)
10 050 0.0 -0 5 0
Figure 4-17. Cyclic Voltammograms of NADH (Fig, A) and NAD (Fig, B) in the 
Current Liquid Chromatographic Solvent at a Carbon Paste Electrode, Fig, B is 
virtually identical to what is obtained with the solvent alone.
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inj ect
Figure 4-18. Chromatograms Illustrating the Retention of NADH. Fig. A 
is from a working standard solution with added NADH. Fig. B is from an 
incubation mixture. Peaks: solvent (1), NADH (2), DA (3), DB (4),
DOPAC (5).
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the incubation mixture shows a peak with the same capacity factor as
authentic NADH. The relatively small size of the NADH peak in such
mixtures can be explained by the relatively high peak potential for
NADH and the fact that its oxidation only involves a one electron
transfer compared to the 2  electron process associated with catechol 
38
oxidation. Thus, a loss in sensitivity and detection limits will 
likely result for MAO determinations employing indirect NADH measurements. 
B. Summary
The analysis of MAO activity in tissue samples by LCEC appears 
to have a number of advantages over existing procedures. The analysis 
is relatively simple, inexpensive, and involves only a minimum amount 
of sample manipulation. As many as 40 samples can conveniently be 
handled by a single operator in one day. As presently configured, 
this assay can also employ a variety of substrates either individually 
or simultaneously.
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APPENDIX Al
SYNTHESIS OF 5-HYDROXYINDOLE-3-CARBOXYLIC ACID
I. INTRODUCTION
The preparation of 5-hydroxylndole-3-carboxylic acid (5-HICA)
was adapted from the work of Marchelli et al.  ^who produced the
material from 5-benzyloxyindole(I) (Fig. Al-1). The synthesis is based
on the formation of 5-benzyloxy-3-carbethoxyindole(III) by reacting the
starting material with a Grignard reagent and subsequently esterifying
with ethylchloroformate. The mixture, containing esterified indoles
(II and III) and starting material, is then subjected to hydrolysis
with aqueous alkali, wherein compound III is hydrolyzed into 5-benzyl-
oxyindole-3-carboxylic acid(IV). Indole II is converted into the
62starting compound (I) during this hydrolysis. Finally, the purified 
product is debenzylated into 5-HICA(V) by catalytic hydrogenation.
II. REAGENTS
The following chemicals were obtained from Aldrich Chemical 
Co., Milwaukee, WS in the highest purity available. They were used 
without further purification:
5-benzyloxyindole 
iodoethane 
ethylchloroformate
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(Ml) (1. KOH) 
(2. HCl)(1. KOH) (2. HCl)
COOH
( IV )
HO, COOH
( V )
Figure Al-1. Synthesis of 5-hydroxyindole-3-carboxylic Acid.
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MCB of Cincinnati, OH, supplied the 10% palladium on charcoal. 
All other compounds were obtained at the highest available purity from 
commercial sources. These included iodine, magnesium turnings, ethyl 
ether, ethyl alcohol, potassium hydroxide, methanol, sodium bicarbonate, 
anhydrous sodium sulfate, and n-propanol.
III. PROCEDURE
Rxn 1. Formation of Grignard Compounds
The reaction apparatus, similar to that illustrated in Fig.
Al-2, was dried at 110°C for 1 hr, assembled while warm, and purged 
with dry nitrogen. 0.92 grams of magnesium turnings, 30 mis of 
anhydrous ethyl ether, and 4.8 mis of iodoethane were added to the 
round bottom flask through the right hand neck. The reaction proceeded 
very quickly at room temperature, and cooling with crushed ice was 
necessary to moderate the rate of reaction. After all the magnesium 
had disappeared, the solution was a pale yellow/black in color.
4.4 grams of the starting material, 5-benzyloxyindole(.1), 
was weighed out and dissolved into 1 0 0  mis of anhydrous ethyl ether.
The solution was cooled to 5°C, and the indole was added dropwise with 
stirring through the separatory funnel. After the addition of starting 
material, the reaction mixture was refluxed carefully for 90 min, 
after which the heating mantel was removed and the solution cooled to 
0°C by immersion in crushed ice. The flask contained two layers: 
a brown bottom layer under a clear greenish-yellow top layer.
Rxn 2. Formation of Benzyloxycarbethoxyindoles
Into the cold mixture from rxn 1, 2.1 ml of ethyl chloroformate
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with
conc. HgSOjji
in
/
Joints
125 ml separatory 
funnel
pTubher septum 
luer-lock syringe
Drierite'
with
ground
flask with 
ground glass Joints
iT„ out
•mineral oil
Figure Al-2. Reaction Vessel for Synthesis of 5-benzylcarbethoxyindole.
luer lock syringes
/rubber septum
out
rfl >
ml flask
Figure Al-3. Reaction Vessel for Recrystallization of 5-hydroxyindole- 
3-carboxylic Acid.
164
in 2 0  ml of anhydrous ethyl ether was added dropwise while stirring 
through the separatory funnel. This addition took ca. 30 min. After 
the addition was complete, the solution was poured into a 1  liter 
separatory funnel containing ca. 100 of a 50:50 ice and water 
mixture. The contents were shaken vigorously, and an emulsion appeared. 
After standing, the ether layer (pale yellow) separated and was saved. 
The water layer was washed three times with 50 ml portions of fresh 
ether. The combined ether rinsings were washed three times with a 50 
ml portion of a saturated solution of sodium bicarbonate and then 
dried with anhydrous sodium sulfate. The ether was then removed using 
a rotary evaporator, leaving a pale yellow solid (5.1 grams, crude 
product).
Rxn 3. Formation of 5-benzyloxyindole-3-carboxylic acid
2.0 grams of crude product from rxn 2, 150 mis of n-propanol,
15 mis of ethanol, and 70 mis of 2 M KOH were placed into a 500 ml round 
bottom flask fitted with a reflux condenser and heated for 5 hrs at 
75°C in a mineral oil bath. The heat was removed and the estérification 
process was allowed to continue at room temperature, with stirring, for 
24 hrs. The yellow/brown reaction mixture was removed and the volume 
was reduced to ca. 10 ml using the rotory evaporator. A sandy, 
yellow precipitate was observed to form at this point. The flask 
was removed from the rotovap, and 2 0 0  ml of ice water and 1 0 0  ml 
of cold ethyl ether were added. Two phases appeared (the top, a dark 
yellow ether layer, and the bottom, a light yellow aqueous layer).
The water layer was separated using a 500 ml separatory funnel; it
165
was washed with two 50 ml portions of ether to remove the last traces 
of starting material. Approximately 70 ml of 2 M HCl were added, 
lowering the pH of the solution to 3 as measured with litmus paper. At 
this pH, a white precipitate formed, representing the carboxylic acid (IV). 
The aqueous layer, containing the precipitate, was then extracted 3 times 
with 50 ml portions of ether to collect the product. The combined ether 
extracts were placed on the rotary evaporator and the solvent removed, 
leaving a yellow solid. The solid was dissolved in ca. 50 ml of hot 
ethanol, filtered while hot, and placed in the refrigerator for crystal­
lization. The melting point of the impure crystals was 190®C. The 
crystals were redissolved in 4.0 ml of hot ethanol, and the solution 
was placed back into the refrigerator. Crystals, which again formed 
within 1  hr, were filtered off using a suction flask and placed in a 
vacuum desiccator to dry. The final yield was 22% based upon the starting 
material (M.P. 200°C).
Rxn 4. Formation of 5-hydroxyindole-3-carhoxylic acid
This part of the synthesis proved to be the most difficult due 
to the sensitivity of the debenzylated product to oxygen. Extreme care 
was taken during the procedure to ensure that all oxygen was excluded from 
the recrystallization flask. The incorporation of a dry box for future 
work is strongly suggested.
Into a 50 ml round bottom flask, 15 ml of methanol and a 
small magnetic stirring bar were added. The flask was then purged 
with nitrogen. 0.125 grams of 10% palladium on charcoal were added 
along with 250 mg of the product from rxn 3. Extreme care was taken 
when adding the catalyst. All oxygen must he removed prior to the
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addition of the palladium or a violent reaction will ensue. Once the 
three ingredients were added, the mixture was placed on the hydrogenator 
and stirred magnetically at atmospheric pressure for 30 min. After 
the hydrogenation was complete, the catalyst was removed by filtration 
with celite and concentrated to dryness on the rotory evaporator.
Care was exercised to use as little heat as possible when removing 
the methanol. After the protecting group is removed from the indole, 
the compound is very susceptible to air oxidation in solution. And, 
this oxidation process appears to be highly accelerated at elevated 
temperatures.
Once the methanol was removed, the flask was tightly stoppered 
with a rubber septum and the flask fitted with nitrogen (Fig. Al-3). 
Ethanol (ca. 0.5 ml) was added until the solid just dissolved. Toluene 
(ca. 4.0 ml) was then added until a cloudiness appeared, and the flask 
was refrigerated overnight. The next morning an oil was observed in 
the flask and was discarded. The remaining liquid was placed onto the 
rotovap and removed, leaving a white solid. The solid was redissolved 
in ethanol, and toluene was again added. The solution was scratched 
and placed in the refrigerator for recrystallization. The melting 
point of the resulting crystals was 180®C, which compares favorably 
to the literature value of 180®C.^ A yield of 70% was obtained for 
this step.
Instrumental observations providing structural verification 
of the product are presented in Table Al-1. Cyclic voltammetry on 
the compound exhibited a much more easily oxidized substance when 
compared to the benzylated precursor run under identical conditions.
Table Al-1. Experimental Data for 5-HICA
Mol. Wt. Melting Pt. Infrared (cm
2
Mass Spec
(Cyclic Vo?tammetry)
177 180°C 3300(broad); 
1630(st); 1655(st)
largest four: 
104.1(27.3), 105.1(20.4) 
177.0(15.6), 133.0(100)
0.25V^
Measured versus SCE at pyrolytic graphite electrode in pH 4.5 acetate buffer
2  M
Numbers in parentheses represent % abundance vs. the base peak of 133. 5
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The IR spectrum (KBr pellet) confirmed the presence of a hydroxylated 
aromatic system and a carbonyl group.
APPENDIX A2
TROUBLESHOOTING THE LCEC
I. INTRODUCTION
Since the initial work of Kissinger et al. the analytical 
technique of liquid chromatography with electrochemical detection (LCEC) 
has experienced a steady increase in popularity. A recent review on 
LCEC describes upwards of 300 papers on the s u b j e c t . T h e  majority 
of these publications involve analytical applications of LCEC, but 
there have also been discussions on the improvement, understanding, 
and future directions of LCEC.^^’^ ^ However, even with the knowledge 
we now possess, there are still many questions which have been left 
unanswered concerning the electrochemical detector. In developing 
LCEC applications, unusual and paradoxical chromatograms occasionally 
emerged from the strip chart recorder, leaving us scratching our heads 
over what appeared as a temporary enigma. When the pen took a turn 
for the worst, the typical reaction was to wiggle wires and electrodes 
or tap the side of the electrode's plexiglass body in a rather un­
systematic fashion until a normal state of affairs reappeared.
The following report is an attempt to relieve some of the 
anxiety associated with the use of LCEC by exhibiting the sources 
of a number of problems that have appeared over the past three years.
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These Illustrations are meant to be useful in a diagnostic nature, and 
will be accompanied by a brief discussion of what occurred within the 
LCEC system, followed by a description of how to restore the chromato­
graph into a normal state of affairs. The data is very empirical in 
nature; the actual solution to the problem encountered often appeared 
only after extensive tapping, wiggling, and reassembling.
II. Experimental
The LCEC system has been previously described in the preceding 
chapters.
III. Results
The problems which can affect an LCEC can be classified into four 
general categories according to the particular area of the chromatograph 
in which they arise. These areas are: 1) the chromatographic solvent
and column, 2) the electrochemical detector, 3) the chromatographic 
pump, and 4) the supporting electronics.
Fig. A2-1 represents a normal state of affairs for an LCEC system 
operating at a high sensitivity, i.e., 0.1 na/inch on the recorder. The 
attainment of these conditions is what the chromatographer strives for, 
and the following results are presented with suggested actions to 
reestablish this condition when a malfunction does appear.
A. Problems Associated with the Solvent and Column
Fig. A2-2 illustrates three problems normally associated with 
the liquid chromatography portion of the LCEC. Fig. A2-2A is a 
chromatogram demonstrating a chromatographic solvent system which has
171
.OSna
20 •min
Figure A2-1. Typical Chromatographic Baseline at High Sensitivity.
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Figure A2-2. Chromatograms Illustrating Problems with Chromatographic 
Solvents and Columns. Pig. A is baseline from a nonequilibrated LCEC 
system. Fig. B is the result of oxidizable impurities in the LCEC system. 
Fig. C is caused by channeling.
Chromatographic
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not been allowed sufficient time to establish equilibrium with the 
column or electrochemical detector. The symptoms are either an 
ascending or descending baseline which is relatively free of "noise." 
Continued pumping of the solvent with the EC detector in place will 
eventually correct this situation.
A dirty column or chromatographic system creates a chromatogram 
similar to that shown in Fig. A2-2B. As impurities bleed from the 
contaminated area and elute into the detector, spurious peaks appear 
on the strip chart recorder. The rather obvious solution is to replace 
the chromatographic solvent and completely flush the system and injection 
device. Alternatively, the column may be cleaned with methanol/water 
as described in Table A2-1.
Fig. A2-2C is a chromatogram of three compounds, each resulting 
in a doublet peak. This condition is believed to be due to channeling 
within the column. The solute molecules are diverted into two separate 
paths and emerge from the colimin at slightly different times, producing 
two closely spaced peaks. When this situation occurs, the column 
should be cleaned with a 70% methanol/water solution (see Table A2-1).
B. Problems Associated with the EC Detector
Over a period of time, the polished surface of the carbon paste 
electrode begins to deteriorate. Small pieces of the electrode surface 
may be chipped away into the chromatographic stream exposing fresh, 
electroactive sites on the electrode surface. The result of this 
deterioration is illustrated in Fig. A2-3A as producing a very jagged 
and noisy baseline. The electrode should be rebuilt by wiping the
174
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20
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Figure A2-3. Chromatograms Illustrating Malfunctions of the EC Detector. 
Fig. A was associated with a poorly surfaced working electrode. Fig. B 
was caused by a bad reference electrode.
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Table A2-1. Procedure for Rejuvinating Microparticulate Columns
1. Stop pump and place filtered distilled water into solvent reservoir.
2. Disconnect EC detector and all plastic components at the outlet of 
the column and start pump.
3. Flush system with distilled water for a minimum of 1 hour to remove 
last traces of inorganic/organic salts from buffer.
4. Stop pump and fill solvent reservoir with a 70% (v/v) methanol/ 
water mixture and start pump.
5. Pump the methanol solution through the system at ca. 1 ml/min for 
a minimum of 4 hours (preferably overnight).
6. Reverse procedure to replace fresh chromatographic solvent.
old surface gently with a paper towel and resurfacing with fresh carbon 
paste. It should be noted that only the top 0.1 mm of carbon need by 
removed. This greatly diminishes the amount of time needed for 
equilibration of the reconstructed electrode vrith the chromatographic 
system. It is frequently the case that many resurfacing attempts are 
required to produce a smooth, noiseless electrode.
Fig. A2-3B represents the baseline obtained from an LCEC system 
after extensive use with a small Ag/AgCl reference electrode. The 
fluctuations in the baseline are believed to be due to a nonpolarization 
of the reference electrode. A flat baseline returned after the reference 
electrode was replaced with a larger saturated calomel electrode (SCE).
A common nuisance in LCEC is air bubbles forming within the EC 
detector. Figure A2-4 shows two chromatograms obtained when large 
air bubbles passed through the detector and either struck the reference
176
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Figure A2-4. Chromatograms Illustrating Air Bubbles Within the EC Detector. 
Fig. A. Air bubbles striking the reference electrode. Fig. B. Air bubbles 
collecting on the tip of the reference electrode. Fig. C. Air bubbles 
streaming across the working electrode surface.
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electrode (Fig. A) or collected on the Vycor tip of the reference elec­
trode (Fig. B). Fig. A2-4C is a chromatogram representing a condition in 
which a regular stream of tiny air bubbles flowed over the working 
electrode. To help prevent these tiny bubbles from forming in the LCEC 
system, we recommend that the eluting solvent be deaerated prior to 
use. This is particularly important for solvents containing methanol. 
Generally, filtration using an aspirator has been found satisfactory for 
this purpose. Air bubbles may also be introduced when changing solvents 
or electrodes. Following these operations, it is very important to 
check for air pockets trapped within the working electrode or the com­
partment containing the reference electrode. Any such air can usually 
be removed by simply gently tapping the electrode with the handle of a 
screwdriver.
C. Problems with the Pump.
Most problems associated with the hydraulic portions of the 
LCEC are easily discernible. Leaking fittings, low flow rates, and 
low operating pressures are easily attributed to a malfunctioning pump 
or the associated hardware.
A problem that is not so easily recognized and which often 
occurs with double reciprocating pumps involves trapped air in a pump 
head (see Fig. A2-5). This situation most frequently develops when 
changing solvents and sufficient care is not taken to remove air from 
the solvent inlet lines. In addition to the chromatogram shown in 
Fig. A 2-5, this condition may also be observed as an abnormal drop 
in operating pressure accompanied by a low flow rate. To remove trapped
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Figure A2-5. Chromatogram Illustrating Trapped Air in Pump Head.
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air in the pump, the outlet, or high pressure, side is disconnected 
and solvent is pumped through the head at a high flow rate for a few 
minutes.
D. Problems with the Electronics
Our experience with the associated electronics has shown these 
hardware components to be extremely resilient during extended periods 
of continuous use. One distinctive problem was easily traced to a 
failure of the power supply (see Fig. A2-6A). Some minor problems have 
also been observed, although these can normally be ascribed to operator 
failure. Forgetting to turn on the power supply or improperly connecting 
the EC detector to the electronics are represented by an extremely flat, 
almost noiseless baseline (Fig. A2-6B). A poor connection to the 
recorder (Fig. A2-6C) also produces flat baselines although in this 
case they are typically accompanied by large, sudden spikes.
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Figure A2-6. Chromatograms Illustrating Electrical Malfunctions. Fig. A 
was the result of a power supply failure. Fig. B is a baseline from a 
detector with no applied potential. Fig. C is a baseline obtained from 
a recorder with poor electrical connections to the associated electronics.
